https://trial.medpath.com/news/tusamitamab-ravtansine-misses-survival-end-points-in-advanced-nsclc-trial-onclive 2024-09-11T13:34:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tusamitamab-ravtansine-misses-survival-end-points-in-advanced-nsclc-trial-onclive 2024-09-11T13:34:05+00:00 weekly 0.7 https://trial.medpath.com/news/pathologists-call-for-reform-in-her2-testing-standards-as-breast-cancer-treatment-landscape-evolves 2024-09-11T13:25:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pathologists-call-for-reform-in-her2-testing-standards-as-breast-cancer-treatment-landscape-evolves 2024-09-11T13:25:09+00:00 weekly 0.7 https://trial.medpath.com/news/enterprise-therapeutics-appoints-annabella-amatulli-as-head-of-regulatory-affairs 2024-09-11T13:18:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enterprise-therapeutics-appoints-annabella-amatulli-as-head-of-regulatory-affairs 2024-09-11T13:18:07+00:00 weekly 0.7 https://trial.medpath.com/news/improving-lung-cancer-clinical-trial-design-tech-can-help-but-relationships-are-key 2024-09-11T13:15:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/improving-lung-cancer-clinical-trial-design-tech-can-help-but-relationships-are-key 2024-09-11T13:15:02+00:00 weekly 0.7 https://trial.medpath.com/news/pharmala-to-supply-johns-hopkins-medicine-for-clinical-trial-globenewswire 2024-09-11T13:05:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmala-to-supply-johns-hopkins-medicine-for-clinical-trial-globenewswire 2024-09-11T13:05:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-gives-approval-for-duchenne-muscular-dystrophy-pediatric-treatment-science-2-0 2024-09-11T13:03:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-gives-approval-for-duchenne-muscular-dystrophy-pediatric-treatment-science-2-0 2024-09-11T13:03:06+00:00 weekly 0.7 https://trial.medpath.com/news/theradaptive-announces-first-patient-treated-in-oasis-clinical-trial-of 2024-09-11T13:00:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/theradaptive-announces-first-patient-treated-in-oasis-clinical-trial-of 2024-09-11T13:00:48+00:00 weekly 0.7 https://trial.medpath.com/news/comprehensive-cancer-research-from-dana-farber-to-lead-esmo-congress-2024 2024-09-11T12:43:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comprehensive-cancer-research-from-dana-farber-to-lead-esmo-congress-2024 2024-09-11T12:43:38+00:00 weekly 0.7 https://trial.medpath.com/news/painreform-ltd-confirms-sutures-compatibility-in-human-clinical-trials-for-prf-110 2024-09-11T12:40:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/painreform-ltd-confirms-sutures-compatibility-in-human-clinical-trials-for-prf-110 2024-09-11T12:40:22+00:00 weekly 0.7 https://trial.medpath.com/news/ss-innovations-conducts-interactive-meeting-with-the-center-for-devices-and-yahoo-finance 2024-09-11T12:40:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ss-innovations-conducts-interactive-meeting-with-the-center-for-devices-and-yahoo-finance 2024-09-11T12:40:19+00:00 weekly 0.7 https://trial.medpath.com/news/allergan-aesthetics-launches-botox-r-cosmetic-onabotulinumtoxina-for-masseter 2024-09-11T12:33:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/allergan-aesthetics-launches-botox-r-cosmetic-onabotulinumtoxina-for-masseter 2024-09-11T12:33:49+00:00 weekly 0.7 https://trial.medpath.com/news/nuance-pharma-completes-recruitment-for-enhance-china-the-phase-3-clinical-trial-of 2024-09-11T12:03:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nuance-pharma-completes-recruitment-for-enhance-china-the-phase-3-clinical-trial-of 2024-09-11T12:03:22+00:00 weekly 0.7 https://trial.medpath.com/news/bio-thera-solutions-and-biogen-publish-phase-3-clinical-trial-data-for-tofidence 2024-09-11T12:01:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bio-thera-solutions-and-biogen-publish-phase-3-clinical-trial-data-for-tofidence 2024-09-11T12:01:05+00:00 weekly 0.7 https://trial.medpath.com/news/b-riley-raises-viridian-therapeutics-shares-target-on-phase-iii-thrive-study-investing-com 2024-09-11T11:51:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/b-riley-raises-viridian-therapeutics-shares-target-on-phase-iii-thrive-study-investing-com 2024-09-11T11:51:22+00:00 weekly 0.7 https://trial.medpath.com/news/searching-for-a-vaccine-against-east-coast-fever-tu-braunschweig-blogs 2024-09-11T11:26:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/searching-for-a-vaccine-against-east-coast-fever-tu-braunschweig-blogs 2024-09-11T11:26:03+00:00 weekly 0.7 https://trial.medpath.com/news/agios-announces-fda-orphan-drug-designation-granted-to-tebapivat-ag-946-for-stock-titan 2024-09-11T11:08:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/agios-announces-fda-orphan-drug-designation-granted-to-tebapivat-ag-946-for-stock-titan 2024-09-11T11:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-and-regeneron-s-dupixent-succeeds-in-trial-of-chronic-hives-stat-news 2024-09-11T11:02:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-and-regeneron-s-dupixent-succeeds-in-trial-of-chronic-hives-stat-news 2024-09-11T11:02:42+00:00 weekly 0.7 https://trial.medpath.com/news/viridian-therapeutics-stock-jumps-after-phase-iii-trial-met-all-endpoints-yahoo-finance 2024-09-11T10:57:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viridian-therapeutics-stock-jumps-after-phase-iii-trial-met-all-endpoints-yahoo-finance 2024-09-11T10:57:48+00:00 weekly 0.7 https://trial.medpath.com/news/arch-biopartners-announces-alberta-health-services-approval-to-proceed-with-phase-ii-trial 2024-09-11T10:49:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arch-biopartners-announces-alberta-health-services-approval-to-proceed-with-phase-ii-trial 2024-09-11T10:49:57+00:00 weekly 0.7 https://trial.medpath.com/news/patient-insights-into-the-decentralisation-of-clinical-trials-european-pharmaceutical-review 2024-09-11T10:44:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-insights-into-the-decentralisation-of-clinical-trials-european-pharmaceutical-review 2024-09-11T10:44:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rejects-mdma-treatment-for-ptsd-setbacks-and-new-directions-lexology 2024-09-11T10:16:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-rejects-mdma-treatment-for-ptsd-setbacks-and-new-directions-lexology 2024-09-11T10:16:18+00:00 weekly 0.7 https://trial.medpath.com/news/belantamab-mafodotin-pomalidomide-and-dexamethasone-for-triple-class-exposed-nature 2024-09-11T10:08:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/belantamab-mafodotin-pomalidomide-and-dexamethasone-for-triple-class-exposed-nature 2024-09-11T10:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/praxis-stock-poised-for-growth-after-key-pipeline-progress-analyst-says-investing-com 2024-09-11T09:56:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/praxis-stock-poised-for-growth-after-key-pipeline-progress-analyst-says-investing-com 2024-09-11T09:56:17+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-therapy-won-t-raise-odds-for-a-second-cancer-study-finds 2024-09-11T09:09:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-therapy-won-t-raise-odds-for-a-second-cancer-study-finds 2024-09-11T09:09:55+00:00 weekly 0.7 https://trial.medpath.com/news/daily-pill-helps-people-lose-weight-combines-glp-1-with-other-drug 2024-09-11T09:09:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daily-pill-helps-people-lose-weight-combines-glp-1-with-other-drug 2024-09-11T09:09:21+00:00 weekly 0.7 https://trial.medpath.com/news/blood-test-could-gauge-your-odds-for-lung-trouble-like-copd 2024-09-11T09:09:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blood-test-could-gauge-your-odds-for-lung-trouble-like-copd 2024-09-11T09:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/sec-form-10-q-filed-by-engene-holdings-inc-quantisnow 2024-09-11T08:52:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sec-form-10-q-filed-by-engene-holdings-inc-quantisnow 2024-09-11T08:52:33+00:00 weekly 0.7 https://trial.medpath.com/news/prodrugs-and-patents-enhancing-therapy-adherence-and-reducing-side-effects 2024-09-11T08:09:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prodrugs-and-patents-enhancing-therapy-adherence-and-reducing-side-effects 2024-09-11T08:09:05+00:00 weekly 0.7 https://trial.medpath.com/news/september-11-2024-harmonie-and-a-new-approach-to-commercial-clinical-trials-in 2024-09-11T08:06:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/september-11-2024-harmonie-and-a-new-approach-to-commercial-clinical-trials-in 2024-09-11T08:06:31+00:00 weekly 0.7 https://trial.medpath.com/news/never-give-up-treatment-breakthroughs-arrive-for-sclc-cure-today 2024-09-11T07:18:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/never-give-up-treatment-breakthroughs-arrive-for-sclc-cure-today 2024-09-11T07:18:15+00:00 weekly 0.7 https://trial.medpath.com/news/radiprodil-significantly-reduces-seizure-frequency-in-phase-1b-honeycomb-study-of 2024-09-11T07:10:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiprodil-significantly-reduces-seizure-frequency-in-phase-1b-honeycomb-study-of 2024-09-11T07:10:28+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-provides-update-on-phase-i-ii-therapeutic-herpes-simplex-virus-hsv-vaccine-trial 2024-09-11T06:03:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-provides-update-on-phase-i-ii-therapeutic-herpes-simplex-virus-hsv-vaccine-trial 2024-09-11T06:03:53+00:00 weekly 0.7 https://trial.medpath.com/news/healthcare-discrimination-study-reveals-multiple-barriers-for-sickle-cell-disease-patients 2024-09-11T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/healthcare-discrimination-study-reveals-multiple-barriers-for-sickle-cell-disease-patients 2024-09-11T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bioversys-announces-strategic-investment-from-gibf2-and-launch-of-bv100-clinical 2024-09-11T05:46:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioversys-announces-strategic-investment-from-gibf2-and-launch-of-bv100-clinical 2024-09-11T05:46:45+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-is-the-first-and-only-biologic-to-achieve-significant-improvements-in 2024-09-11T05:46:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-dupixent-is-the-first-and-only-biologic-to-achieve-significant-improvements-in 2024-09-11T05:46:44+00:00 weekly 0.7 https://trial.medpath.com/news/study-links-anti-ttg-and-ema-antibodies-to-fibromyalgia-risk-in-celiac-disease-patients 2024-09-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-links-anti-ttg-and-ema-antibodies-to-fibromyalgia-risk-in-celiac-disease-patients 2024-09-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/piflufolastat-18f-enters-commercial-market-in-spain-urology-times 2024-09-11T04:32:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/piflufolastat-18f-enters-commercial-market-in-spain-urology-times 2024-09-11T04:32:24+00:00 weekly 0.7 https://trial.medpath.com/news/investors-are-waking-up-to-centessa-s-sleepiness-drug-biopharma-dive 2024-09-11T04:15:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investors-are-waking-up-to-centessa-s-sleepiness-drug-biopharma-dive 2024-09-11T04:15:49+00:00 weekly 0.7 https://trial.medpath.com/news/expert-reaction-to-conference-abstract-from-a-phase-1-study-on-safety-tolerability-and-weight 2024-09-11T04:12:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-reaction-to-conference-abstract-from-a-phase-1-study-on-safety-tolerability-and-weight 2024-09-11T04:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-significant-understaging-in-early-stage-pancreatic-cancer-diagnosis 2024-09-11T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-significant-understaging-in-early-stage-pancreatic-cancer-diagnosis 2024-09-11T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-not-alarmed-by-obesity-drug-s-side-effects-r-d-head-says-swi-swissinfo-ch 2024-09-11T03:55:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-not-alarmed-by-obesity-drug-s-side-effects-r-d-head-says-swi-swissinfo-ch 2024-09-11T03:55:39+00:00 weekly 0.7 https://trial.medpath.com/news/a-novo-nordisk-weight-loss-drug-lowers-bmi-in-kids-as-young-as-6-nbc-news 2024-09-11T02:15:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-novo-nordisk-weight-loss-drug-lowers-bmi-in-kids-as-young-as-6-nbc-news 2024-09-11T02:15:53+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-experimental-obesity-pill-has-mild-to-moderate-side-effects-in-early-trial 2024-09-11T01:47:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-experimental-obesity-pill-has-mild-to-moderate-side-effects-in-early-trial 2024-09-11T01:47:37+00:00 weekly 0.7 https://trial.medpath.com/news/skyhawk-therapeutics-to-present-additional-positive-topline-data-from-parts-a-and-b-of-phase-1-clinical-trial-of-sky-0515-at-european-huntington-s-disease-network-and-enroll-hd-2024 2024-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/skyhawk-therapeutics-to-present-additional-positive-topline-data-from-parts-a-and-b-of-phase-1-clinical-trial-of-sky-0515-at-european-huntington-s-disease-network-and-enroll-hd-2024 2024-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cellworks-biosimulation-platform-predicts-chemotherapy-benefit-in-nsclc-patients-beyond-pd-l1-status 2024-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cellworks-biosimulation-platform-predicts-chemotherapy-benefit-in-nsclc-patients-beyond-pd-l1-status 2024-09-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/highly-accurate-telix-s-phase-iii-zircon-trial-for-kidney-cancer-imaging-published-in-the 2024-09-10T22:48:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/highly-accurate-telix-s-phase-iii-zircon-trial-for-kidney-cancer-imaging-published-in-the 2024-09-10T22:48:29+00:00 weekly 0.7 https://trial.medpath.com/news/prophylactic-dexamethasone-regimen-reduces-infusion-related-globenewswire 2024-09-10T22:21:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prophylactic-dexamethasone-regimen-reduces-infusion-related-globenewswire 2024-09-10T22:21:49+00:00 weekly 0.7 https://trial.medpath.com/news/walgreens-boots-alliance-inc-wba-td-cowen-9th-annual-futurehealth-conference-transcript 2024-09-10T22:16:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/walgreens-boots-alliance-inc-wba-td-cowen-9th-annual-futurehealth-conference-transcript 2024-09-10T22:16:20+00:00 weekly 0.7 https://trial.medpath.com/news/dr-leighl-on-patient-satisfaction-and-resource-utilization-from-paloma-3-in-nsclc 2024-09-10T22:04:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-leighl-on-patient-satisfaction-and-resource-utilization-from-paloma-3-in-nsclc 2024-09-10T22:04:57+00:00 weekly 0.7 https://trial.medpath.com/news/avistone-announces-results-from-a-sponsored-clinical-research-program-studying-morningstar 2024-09-10T21:56:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avistone-announces-results-from-a-sponsored-clinical-research-program-studying-morningstar 2024-09-10T21:56:39+00:00 weekly 0.7 https://trial.medpath.com/news/easd-2024-cardiovascular-and-inflammatory-markers-reduce-after-orforglipron-treatment 2024-09-10T21:44:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/easd-2024-cardiovascular-and-inflammatory-markers-reduce-after-orforglipron-treatment 2024-09-10T21:44:51+00:00 weekly 0.7 https://trial.medpath.com/news/dexamethasone-reduces-infusion-related-reactions-in-patients-with-egfr-mutated-non-placera 2024-09-10T21:20:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dexamethasone-reduces-infusion-related-reactions-in-patients-with-egfr-mutated-non-placera 2024-09-10T21:20:44+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-update-august-2024-approvals-designations-and-clearances 2024-09-10T21:05:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-action-update-august-2024-approvals-designations-and-clearances 2024-09-10T21:05:56+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-receives-fda-s-regenerative-medicine-advanced-therapy-rmat-designation 2024-09-10T20:50:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-receives-fda-s-regenerative-medicine-advanced-therapy-rmat-designation 2024-09-10T20:50:48+00:00 weekly 0.7 https://trial.medpath.com/news/tofacitinib-effective-for-ankylosing-spondylitis-regardless-of-baseline-crp-level 2024-09-10T20:46:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tofacitinib-effective-for-ankylosing-spondylitis-regardless-of-baseline-crp-level 2024-09-10T20:46:45+00:00 weekly 0.7 https://trial.medpath.com/news/rate-of-cardiovascular-adverse-events-myocarditis-may-be-low-in-trials-assessing-icis 2024-09-10T20:06:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rate-of-cardiovascular-adverse-events-myocarditis-may-be-low-in-trials-assessing-icis 2024-09-10T20:06:57+00:00 weekly 0.7 https://trial.medpath.com/news/mirvetuximab-soravtansine-shows-efficacy-in-ovarian-cancer-despite-dose-adjustments 2024-09-10T19:09:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mirvetuximab-soravtansine-shows-efficacy-in-ovarian-cancer-despite-dose-adjustments 2024-09-10T19:09:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-sonic-incytes-velacur-r-determined-fat-fraction-vdff-a 2024-09-10T18:12:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-510-k-clearance-to-sonic-incytes-velacur-r-determined-fat-fraction-vdff-a 2024-09-10T18:12:19+00:00 weekly 0.7 https://trial.medpath.com/news/pan-covid-new-drug-sns812-achieves-superiority-in-phase-2-study-biospace 2024-09-10T17:55:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pan-covid-new-drug-sns812-achieves-superiority-in-phase-2-study-biospace 2024-09-10T17:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/vasa-therapeutics-lead-drug-candidate-enters-clinical-trials-contract-pharma 2024-09-10T17:54:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vasa-therapeutics-lead-drug-candidate-enters-clinical-trials-contract-pharma 2024-09-10T17:54:04+00:00 weekly 0.7 https://trial.medpath.com/news/overcoming-failures-lessons-from-ipf-clinical-trials-in-the-past-year 2024-09-10T17:43:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/overcoming-failures-lessons-from-ipf-clinical-trials-in-the-past-year 2024-09-10T17:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/dm-clinical-research-partners-with-brain-and-pain-care-and-sleep-care-clinic-for-new 2024-09-10T17:37:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dm-clinical-research-partners-with-brain-and-pain-care-and-sleep-care-clinic-for-new 2024-09-10T17:37:07+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-study-of-taletrectinib-shows-clinically-meaningful-overall-response-and-prweb 2024-09-10T17:17:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-study-of-taletrectinib-shows-clinically-meaningful-overall-response-and-prweb 2024-09-10T17:17:03+00:00 weekly 0.7 https://trial.medpath.com/news/atamyo-dion-foundation-partner-to-expand-lgmd-study-into-us 2024-09-10T17:15:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atamyo-dion-foundation-partner-to-expand-lgmd-study-into-us 2024-09-10T17:15:32+00:00 weekly 0.7 https://trial.medpath.com/news/hope-vs-hype-seeking-truth-in-recent-prilenia-headlines-hdbuzz 2024-09-10T17:08:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hope-vs-hype-seeking-truth-in-recent-prilenia-headlines-hdbuzz 2024-09-10T17:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/tackling-medchem-bias-one-functional-group-at-a-time 2024-09-10T17:04:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tackling-medchem-bias-one-functional-group-at-a-time 2024-09-10T17:04:02+00:00 weekly 0.7 https://trial.medpath.com/news/pridopidine-now-under-review-in-europe-as-huntington-s-treatment 2024-09-10T16:34:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pridopidine-now-under-review-in-europe-as-huntington-s-treatment 2024-09-10T16:34:52+00:00 weekly 0.7 https://trial.medpath.com/news/why-a-promising-breast-cancer-drug-doesn-t-work-and-how-to-improve-it 2024-09-10T16:14:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-a-promising-breast-cancer-drug-doesn-t-work-and-how-to-improve-it 2024-09-10T16:14:15+00:00 weekly 0.7 https://trial.medpath.com/news/patients-with-namd-successfully-switch-from-aflibercept-to-ranibizumab 2024-09-10T15:52:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patients-with-namd-successfully-switch-from-aflibercept-to-ranibizumab 2024-09-10T15:52:48+00:00 weekly 0.7 https://trial.medpath.com/news/reflections-on-neonatal-erythropoietin-neuroprotection-studies-jama-network 2024-09-10T15:34:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reflections-on-neonatal-erythropoietin-neuroprotection-studies-jama-network 2024-09-10T15:34:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-clearance-for-immunis-phase-ii-sarcopenic-obesity-trial-yahoo-finance 2024-09-10T15:14:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-clearance-for-immunis-phase-ii-sarcopenic-obesity-trial-yahoo-finance 2024-09-10T15:14:17+00:00 weekly 0.7 https://trial.medpath.com/news/leapfrog-bio-screens-clinical-stage-drugs-to-jump-into-cancer-markets 2024-09-10T15:11:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leapfrog-bio-screens-clinical-stage-drugs-to-jump-into-cancer-markets 2024-09-10T15:11:05+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-reports-encouraging-nsclc-drug-data-gets-approval-for-eylea-8mg 2024-09-10T15:03:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-reports-encouraging-nsclc-drug-data-gets-approval-for-eylea-8mg 2024-09-10T15:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-for-inherited-retinal-dystrophy-shows-promise-inside-precision-medicine 2024-09-10T14:55:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-for-inherited-retinal-dystrophy-shows-promise-inside-precision-medicine 2024-09-10T14:55:10+00:00 weekly 0.7 https://trial.medpath.com/news/the-relationship-between-participant-diversity-and-dct-use-in-clinical-trials 2024-09-10T14:54:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-relationship-between-participant-diversity-and-dct-use-in-clinical-trials 2024-09-10T14:54:22+00:00 weekly 0.7 https://trial.medpath.com/news/telo-genomics-assessing-mrd-status-in-telo-dmrd-study-biospace 2024-09-10T14:46:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/telo-genomics-assessing-mrd-status-in-telo-dmrd-study-biospace 2024-09-10T14:46:00+00:00 weekly 0.7 https://trial.medpath.com/news/common-diabetes-drug-slows-growth-of-normal-cells-carrying-cancer-mutation-finds-study 2024-09-10T14:44:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/common-diabetes-drug-slows-growth-of-normal-cells-carrying-cancer-mutation-finds-study 2024-09-10T14:44:22+00:00 weekly 0.7 https://trial.medpath.com/news/incannex-healthcare-lands-60-million-financing-deal-green-market-report 2024-09-10T14:43:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/incannex-healthcare-lands-60-million-financing-deal-green-market-report 2024-09-10T14:43:04+00:00 weekly 0.7 https://trial.medpath.com/news/uk-study-lifetime-statin-therapy-proves-cost-effective-for-seniors-regardless-of-cvd-history 2024-09-10T14:30:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-study-lifetime-statin-therapy-proves-cost-effective-for-seniors-regardless-of-cvd-history 2024-09-10T14:30:48+00:00 weekly 0.7 https://trial.medpath.com/news/roivant-creates-new-vant-to-license-bayer-s-pulmonary-hypertension-drug-biospace 2024-09-10T14:22:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roivant-creates-new-vant-to-license-bayer-s-pulmonary-hypertension-drug-biospace 2024-09-10T14:22:59+00:00 weekly 0.7 https://trial.medpath.com/news/buy-rating-justified-for-iterum-therapeutics-amid-anticipated-fda-approval-of-sulopenem-for-uutis 2024-09-10T14:10:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/buy-rating-justified-for-iterum-therapeutics-amid-anticipated-fda-approval-of-sulopenem-for-uutis 2024-09-10T14:10:42+00:00 weekly 0.7 https://trial.medpath.com/news/oncohost-accepted-to-present-poster-demonstrating-prophet-r-s-application-in-renal-cell 2024-09-10T14:10:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncohost-accepted-to-present-poster-demonstrating-prophet-r-s-application-in-renal-cell 2024-09-10T14:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-a-post-fda-approval-analysis-nasdaq-vrna-seeking-alpha 2024-09-10T14:09:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verona-pharma-a-post-fda-approval-analysis-nasdaq-vrna-seeking-alpha 2024-09-10T14:09:33+00:00 weekly 0.7 https://trial.medpath.com/news/travere-therapeutics-stock-target-boosted-buy-rating-held-on-fda-approval-investing-com 2024-09-10T13:58:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/travere-therapeutics-stock-target-boosted-buy-rating-held-on-fda-approval-investing-com 2024-09-10T13:58:42+00:00 weekly 0.7 https://trial.medpath.com/news/five-biotech-news-stories-you-need-to-read-today 2024-09-10T13:31:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/five-biotech-news-stories-you-need-to-read-today 2024-09-10T13:31:43+00:00 weekly 0.7 https://trial.medpath.com/news/zokinvy-lonafarnib-the-only-fda-approved-treatment-for-hutchinson-gilford-progeria 2024-09-10T13:27:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zokinvy-lonafarnib-the-only-fda-approved-treatment-for-hutchinson-gilford-progeria 2024-09-10T13:27:19+00:00 weekly 0.7 https://trial.medpath.com/news/daewoong-pharmaceutical-secures-ind-approval-for-dissolvable-microneedle-growth-hormone-patch 2024-09-10T13:17:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daewoong-pharmaceutical-secures-ind-approval-for-dissolvable-microneedle-growth-hormone-patch 2024-09-10T13:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/know-your-tumor-uncovers-rare-mutation-leads-to-effective-treatment-for-patient 2024-09-10T13:04:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/know-your-tumor-uncovers-rare-mutation-leads-to-effective-treatment-for-patient 2024-09-10T13:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/hyperbaric-oxygen-therapy-for-ulcerative-colitis-inventum-university-of-miami 2024-09-10T13:02:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hyperbaric-oxygen-therapy-for-ulcerative-colitis-inventum-university-of-miami 2024-09-10T13:02:11+00:00 weekly 0.7 https://trial.medpath.com/news/robert-duggan-wins-again-as-summit-lung-cancer-treatment-beats-keytruda-stat-news 2024-09-10T12:45:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/robert-duggan-wins-again-as-summit-lung-cancer-treatment-beats-keytruda-stat-news 2024-09-10T12:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/corvus-pharmaceuticals-initiates-registrational-phase-3-clinical-trial-of-soquelitinib-for 2024-09-10T12:34:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corvus-pharmaceuticals-initiates-registrational-phase-3-clinical-trial-of-soquelitinib-for 2024-09-10T12:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/new-secondary-analysis-of-phase-3-data-demonstrates-sotagliflozin-improves-time-in 2024-09-10T12:30:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-secondary-analysis-of-phase-3-data-demonstrates-sotagliflozin-improves-time-in 2024-09-10T12:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-ingelheim-reports-positive-results-from-trial-of-her2-lung-cancer-drug 2024-09-10T12:27:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-ingelheim-reports-positive-results-from-trial-of-her2-lung-cancer-drug 2024-09-10T12:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/integrative-radiopathomics-model-for-predicting-progression-free-survival-in-patients-with 2024-09-10T12:25:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/integrative-radiopathomics-model-for-predicting-progression-free-survival-in-patients-with 2024-09-10T12:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/man-with-incurable-cancer-among-first-to-undergo-ground-breaking-new-treatment-stv-news 2024-09-10T12:23:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/man-with-incurable-cancer-among-first-to-undergo-ground-breaking-new-treatment-stv-news 2024-09-10T12:23:13+00:00 weekly 0.7 https://trial.medpath.com/news/could-a-pill-help-ease-sleep-apnea 2024-09-10T12:15:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-a-pill-help-ease-sleep-apnea 2024-09-10T12:15:36+00:00 weekly 0.7 https://trial.medpath.com/news/halia-therapeutics-to-present-an-update-on-phase-ii-clinical-trial-data-of-ht-6184-pr-newswire 2024-09-10T12:15:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/halia-therapeutics-to-present-an-update-on-phase-ii-clinical-trial-data-of-ht-6184-pr-newswire 2024-09-10T12:15:06+00:00 weekly 0.7 https://trial.medpath.com/news/reveal-genomics-r-announces-positive-top-line-results-for-her2dx-r-in-cleopatra 2024-09-10T12:14:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reveal-genomics-r-announces-positive-top-line-results-for-her2dx-r-in-cleopatra 2024-09-10T12:14:31+00:00 weekly 0.7 https://trial.medpath.com/news/belite-bio-announces-first-patient-dosed-in-phase-2-3-dragon-ii-trial-of-tinlarebant-for 2024-09-10T12:07:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/belite-bio-announces-first-patient-dosed-in-phase-2-3-dragon-ii-trial-of-tinlarebant-for 2024-09-10T12:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/academic-community-collaboration-improves-multiple-myeloma-treatment-outcomes-experts-report 2024-09-10T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/academic-community-collaboration-improves-multiple-myeloma-treatment-outcomes-experts-report 2024-09-10T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-s-libtayo-shows-durable-survival-benefits-in-phase-3-lung-cancer-study 2024-09-10T11:45:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regeneron-s-libtayo-shows-durable-survival-benefits-in-phase-3-lung-cancer-study 2024-09-10T11:45:39+00:00 weekly 0.7 https://trial.medpath.com/news/quralis-doses-first-participant-cohort-in-phase-1-multiple-ascending-dose-mad-clinical 2024-09-10T11:45:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quralis-doses-first-participant-cohort-in-phase-1-multiple-ascending-dose-mad-clinical 2024-09-10T11:45:39+00:00 weekly 0.7 https://trial.medpath.com/news/europe-sidelines-alzheimer-s-drug-lessons-must-be-learnt-nature 2024-09-10T11:45:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/europe-sidelines-alzheimer-s-drug-lessons-must-be-learnt-nature 2024-09-10T11:45:31+00:00 weekly 0.7 https://trial.medpath.com/news/cardiol-therapeutics-announces-completion-of-the-maveric-phase-ii-study-in-recurrent 2024-09-10T11:40:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiol-therapeutics-announces-completion-of-the-maveric-phase-ii-study-in-recurrent 2024-09-10T11:40:18+00:00 weekly 0.7 https://trial.medpath.com/news/delta-fly-pharma-inc-phase-i-ii-combo-study-of-dfp-10917-with-venetoclax-in-patients 2024-09-10T11:33:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/delta-fly-pharma-inc-phase-i-ii-combo-study-of-dfp-10917-with-venetoclax-in-patients 2024-09-10T11:33:16+00:00 weekly 0.7 https://trial.medpath.com/news/zydus-lifesciences-completes-phase-iia-trial-of-usnoflast-in-als-patients-cnbc-tv18 2024-09-10T11:27:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zydus-lifesciences-completes-phase-iia-trial-of-usnoflast-in-als-patients-cnbc-tv18 2024-09-10T11:27:02+00:00 weekly 0.7 https://trial.medpath.com/news/silo-pharma-announces-completion-of-fda-pre-ind-meeting-to-advance-development-of 2024-09-10T11:07:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/silo-pharma-announces-completion-of-fda-pre-ind-meeting-to-advance-development-of 2024-09-10T11:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/kalvista-pharmaceuticals-to-participate-in-the-2024-cantor-global-healthcare-conference 2024-09-10T11:06:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kalvista-pharmaceuticals-to-participate-in-the-2024-cantor-global-healthcare-conference 2024-09-10T11:06:30+00:00 weekly 0.7 https://trial.medpath.com/news/media-update-ers-dupixent-data-reinforce-clinically-meaningful-benefit-from-pooled 2024-09-10T10:40:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/media-update-ers-dupixent-data-reinforce-clinically-meaningful-benefit-from-pooled 2024-09-10T10:40:54+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-predict-ild-imaging-study-commences-in-interstitial-lung-disease-pharmatimes 2024-09-10T10:34:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2-predict-ild-imaging-study-commences-in-interstitial-lung-disease-pharmatimes 2024-09-10T10:34:12+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-shares-fall-5-on-disappointing-lung-cancer-drug-trial-results-cnbc 2024-09-10T10:15:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-shares-fall-5-on-disappointing-lung-cancer-drug-trial-results-cnbc 2024-09-10T10:15:18+00:00 weekly 0.7 https://trial.medpath.com/news/tc-biopharm-announces-plans-for-monkey-pox-treatment-studies 2024-09-10T10:09:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tc-biopharm-announces-plans-for-monkey-pox-treatment-studies 2024-09-10T10:09:21+00:00 weekly 0.7 https://trial.medpath.com/news/updated-data-from-phase-ii-clinical-trial-of-iruplinalkib-tablets-qixinke-r-presented-at 2024-09-10T10:06:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/updated-data-from-phase-ii-clinical-trial-of-iruplinalkib-tablets-qixinke-r-presented-at 2024-09-10T10:06:03+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-announces-positive-survival-updates-in-phase-2-study-of-thio-in-non 2024-09-10T10:04:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-announces-positive-survival-updates-in-phase-2-study-of-thio-in-non 2024-09-10T10:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/global-exosome-market-size-forecast-trials-and-trends-globenewswire 2024-09-10T09:43:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-exosome-market-size-forecast-trials-and-trends-globenewswire 2024-09-10T09:43:59+00:00 weekly 0.7 https://trial.medpath.com/news/libido-can-drop-after-menopause-but-this-therapy-can-help 2024-09-10T09:09:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/libido-can-drop-after-menopause-but-this-therapy-can-help 2024-09-10T09:09:33+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-advisors-want-iterum-s-antibiotic-indication-narrowed-pink-sheet-citeline 2024-09-10T09:07:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-advisors-want-iterum-s-antibiotic-indication-narrowed-pink-sheet-citeline 2024-09-10T09:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/expert-challenges-benign-classification-of-gleason-6-prostate-cancer-emphasizes-need-for-comprehensive-assessment 2024-09-10T08:56:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-challenges-benign-classification-of-gleason-6-prostate-cancer-emphasizes-need-for-comprehensive-assessment 2024-09-10T08:56:53+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-says-lung-cancer-drug-trial-shows-no-significant-improvement-in-overall-survival 2024-09-10T08:32:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-says-lung-cancer-drug-trial-shows-no-significant-improvement-in-overall-survival 2024-09-10T08:32:37+00:00 weekly 0.7 https://trial.medpath.com/news/study-links-testosterone-to-heightened-covid-19-severity-in-men-through-immune-response-modulation 2024-09-10T06:58:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-links-testosterone-to-heightened-covid-19-severity-in-men-through-immune-response-modulation 2024-09-10T06:58:09+00:00 weekly 0.7 https://trial.medpath.com/news/the-airpods-pro-2-will-soon-double-as-hearing-aids-the-verge 2024-09-10T06:36:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-airpods-pro-2-will-soon-double-as-hearing-aids-the-verge 2024-09-10T06:36:29+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-enters-dmx-200-open-label-extension-study-after-successfully-completing 2024-09-10T06:20:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-enters-dmx-200-open-label-extension-study-after-successfully-completing 2024-09-10T06:20:14+00:00 weekly 0.7 https://trial.medpath.com/news/ose-immunotherapeutics-announces-global-launch-of-artemia-phase-3-registration-study 2024-09-10T06:12:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ose-immunotherapeutics-announces-global-launch-of-artemia-phase-3-registration-study 2024-09-10T06:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-for-sickle-cell-disease-gene-therapy-medical-news-bulletin 2024-09-10T06:01:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-for-sickle-cell-disease-gene-therapy-medical-news-bulletin 2024-09-10T06:01:26+00:00 weekly 0.7 https://trial.medpath.com/news/non-small-cell-lung-cancer-nsclc-clinical-trials-2024-ema-openpr-com 2024-09-10T05:50:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/non-small-cell-lung-cancer-nsclc-clinical-trials-2024-ema-openpr-com 2024-09-10T05:50:56+00:00 weekly 0.7 https://trial.medpath.com/news/hs-20093-generates-responses-in-pretreated-es-sclc-onclive 2024-09-10T05:17:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hs-20093-generates-responses-in-pretreated-es-sclc-onclive 2024-09-10T05:17:20+00:00 weekly 0.7 https://trial.medpath.com/news/novel-proteomics-test-prophet-shows-promise-in-guiding-lung-cancer-immunotherapy-decisions 2024-09-10T05:00:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-proteomics-test-prophet-shows-promise-in-guiding-lung-cancer-immunotherapy-decisions 2024-09-10T05:00:35+00:00 weekly 0.7 https://trial.medpath.com/news/closing-the-gender-diagnostic-gap-with-a-sample-collecting-tampon 2024-09-10T05:00:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/closing-the-gender-diagnostic-gap-with-a-sample-collecting-tampon 2024-09-10T05:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/biotron-updates-on-bit225-012-phase-2-covid-19-clinical-trial-biotech-dispatch 2024-09-10T02:38:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotron-updates-on-bit225-012-phase-2-covid-19-clinical-trial-biotech-dispatch 2024-09-10T02:38:27+00:00 weekly 0.7 https://trial.medpath.com/news/zongertinib-yields-meaningful-responses-in-pretreated-her2-mutated-nsclc 2024-09-10T02:22:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zongertinib-yields-meaningful-responses-in-pretreated-her2-mutated-nsclc 2024-09-10T02:22:11+00:00 weekly 0.7 https://trial.medpath.com/news/type-1-diabetes-uab-startup-gains-fda-clearance-to-test-novel-oral-drug-the-alabama 2024-09-10T02:02:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/type-1-diabetes-uab-startup-gains-fda-clearance-to-test-novel-oral-drug-the-alabama 2024-09-10T02:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-delivers-oral-presentation-of-updated-results-from-a-pivotal-phase-2-pr-newswire 2024-09-10T01:23:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovent-delivers-oral-presentation-of-updated-results-from-a-pivotal-phase-2-pr-newswire 2024-09-10T01:23:45+00:00 weekly 0.7 https://trial.medpath.com/news/sacituzumab-govitecan-generates-responses-with-manageable-safety-profile-in-es-sclc 2024-09-10T01:01:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sacituzumab-govitecan-generates-responses-with-manageable-safety-profile-in-es-sclc 2024-09-10T01:01:55+00:00 weekly 0.7 https://trial.medpath.com/news/how-daratumumab-sc-is-being-perceived-versus-the-iv-form-ppa-dove-medical-press 2024-09-10T00:58:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-daratumumab-sc-is-being-perceived-versus-the-iv-form-ppa-dove-medical-press 2024-09-10T00:58:41+00:00 weekly 0.7 https://trial.medpath.com/news/oxford-scientists-develop-first-cancer-prevention-vaccine-for-lynch-syndrome-patients 2024-09-10T00:01:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oxford-scientists-develop-first-cancer-prevention-vaccine-for-lynch-syndrome-patients 2024-09-10T00:01:46+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-parkinson-s-treatment-personalized-deep-brain-stimulation 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-parkinson-s-treatment-personalized-deep-brain-stimulation 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-evidence-shows-apixaban-reduces-major-bleeding-risk-compared-to-rivaroxaban-in-atrial-fibrillation-patients 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-evidence-shows-apixaban-reduces-major-bleeding-risk-compared-to-rivaroxaban-in-atrial-fibrillation-patients 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eu-chmp-opinions-and-maa-updates-citeline-news-insights 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-chmp-opinions-and-maa-updates-citeline-news-insights 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bevacizumab-addition-to-first-line-chemotherapy-shows-real-world-benefit-in-high-risk-ovarian-cancer 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bevacizumab-addition-to-first-line-chemotherapy-shows-real-world-benefit-in-high-risk-ovarian-cancer 2024-09-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phanes-therapeutics-announces-first-patient-dosed-in-clinical-study-of-pt886-in 2024-09-09T23:52:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phanes-therapeutics-announces-first-patient-dosed-in-clinical-study-of-pt886-in 2024-09-09T23:52:51+00:00 weekly 0.7 https://trial.medpath.com/news/who-still-benefits-from-paxlovid-idsa 2024-09-09T23:38:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-still-benefits-from-paxlovid-idsa 2024-09-09T23:38:25+00:00 weekly 0.7 https://trial.medpath.com/news/medicinova-announces-abstract-regarding-mn-166-ibudilast-in-combat-als-clinical 2024-09-09T23:22:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicinova-announces-abstract-regarding-mn-166-ibudilast-in-combat-als-clinical 2024-09-09T23:22:07+00:00 weekly 0.7 https://trial.medpath.com/news/withings-sleep-rx-receives-fda-clearance-for-home-sleep-apnea-testing 2024-09-09T23:03:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/withings-sleep-rx-receives-fda-clearance-for-home-sleep-apnea-testing 2024-09-09T23:03:49+00:00 weekly 0.7 https://trial.medpath.com/news/sleep-apnea-detection-will-be-on-apple-watches-soon-here-s-how-it-will-work-cnet 2024-09-09T22:54:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sleep-apnea-detection-will-be-on-apple-watches-soon-here-s-how-it-will-work-cnet 2024-09-09T22:54:45+00:00 weekly 0.7 https://trial.medpath.com/news/analysis-further-shows-perioperative-pembrolizumab-efficacy-in-early-stage-nsclc 2024-09-09T22:01:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/analysis-further-shows-perioperative-pembrolizumab-efficacy-in-early-stage-nsclc 2024-09-09T22:01:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-deepwell-digital-therapeutics-software-development-kit-massdevice 2024-09-09T21:32:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-deepwell-digital-therapeutics-software-development-kit-massdevice 2024-09-09T21:32:54+00:00 weekly 0.7 https://trial.medpath.com/news/study-compares-dose-escalation-with-biologics-in-psoriasis-dermatology-times 2024-09-09T21:12:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-compares-dose-escalation-with-biologics-in-psoriasis-dermatology-times 2024-09-09T21:12:19+00:00 weekly 0.7 https://trial.medpath.com/news/aumolertinib-improves-pfs-in-unresectable-stage-iii-egfr-nsclc-after-chemoradiotherapy 2024-09-09T20:52:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aumolertinib-improves-pfs-in-unresectable-stage-iii-egfr-nsclc-after-chemoradiotherapy 2024-09-09T20:52:49+00:00 weekly 0.7 https://trial.medpath.com/news/eyen-shares-are-trading-higher-today-what-you-need-to-know-benzinga 2024-09-09T20:20:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyen-shares-are-trading-higher-today-what-you-need-to-know-benzinga 2024-09-09T20:20:52+00:00 weekly 0.7 https://trial.medpath.com/news/solid-biosciences-tracking-long-term-effects-of-duchenne-muscular-dystrophy-gene 2024-09-09T20:15:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/solid-biosciences-tracking-long-term-effects-of-duchenne-muscular-dystrophy-gene 2024-09-09T20:15:16+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-announces-closing-of-exclusive-worldwide-license-agreement-with 2024-09-09T20:10:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vir-biotechnology-announces-closing-of-exclusive-worldwide-license-agreement-with 2024-09-09T20:10:14+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-plus-chemotherapy-extends-survival-in-lymph-node-only-metastatic-urothelial-cancer 2024-09-09T19:13:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nivolumab-plus-chemotherapy-extends-survival-in-lymph-node-only-metastatic-urothelial-cancer 2024-09-09T19:13:13+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-plus-ccrt-scores-in-east-asian-subgroup-with-cervical-cancer 2024-09-09T19:11:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pembrolizumab-plus-ccrt-scores-in-east-asian-subgroup-with-cervical-cancer 2024-09-09T19:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/stealth-biotherapeutics-announces-fda-advisory-committee-meeting-to-review-biospace 2024-09-09T19:11:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stealth-biotherapeutics-announces-fda-advisory-committee-meeting-to-review-biospace 2024-09-09T19:11:45+00:00 weekly 0.7 https://trial.medpath.com/news/bay-2927088-displays-durable-responses-in-her2-mutated-nsclc-onclive 2024-09-09T19:03:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bay-2927088-displays-durable-responses-in-her2-mutated-nsclc-onclive 2024-09-09T19:03:15+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-study-for-sjogren-s-syndrome-drug-cooperation-between-servier-than-and-clariness 2024-09-09T18:50:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-study-for-sjogren-s-syndrome-drug-cooperation-between-servier-than-and-clariness 2024-09-09T18:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/brigham-led-study-finds-weight-loss-drug-semaglutide-reduced-covid-19-related 2024-09-09T18:29:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brigham-led-study-finds-weight-loss-drug-semaglutide-reduced-covid-19-related 2024-09-09T18:29:06+00:00 weekly 0.7 https://trial.medpath.com/news/agenus-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-morningstar 2024-09-09T18:28:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/agenus-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses-morningstar 2024-09-09T18:28:49+00:00 weekly 0.7 https://trial.medpath.com/news/study-olezarsen-effective-treatment-for-high-triglycerides-mass-general-brigham 2024-09-09T18:20:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-olezarsen-effective-treatment-for-high-triglycerides-mass-general-brigham 2024-09-09T18:20:54+00:00 weekly 0.7 https://trial.medpath.com/news/psilocybin-drug-by-psilera-could-treat-frontotemporal-dementia-without-psychoactive-effects 2024-09-09T18:20:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psilocybin-drug-by-psilera-could-treat-frontotemporal-dementia-without-psychoactive-effects 2024-09-09T18:20:11+00:00 weekly 0.7 https://trial.medpath.com/news/md-anderson-research-highlights-special-edition-2-newswise 2024-09-09T18:11:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/md-anderson-research-highlights-special-edition-2-newswise 2024-09-09T18:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/the-changing-landscape-of-clinical-trials-in-cancer-care-oncology-nursing-news 2024-09-09T18:11:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-changing-landscape-of-clinical-trials-in-cancer-care-oncology-nursing-news 2024-09-09T18:11:33+00:00 weekly 0.7 https://trial.medpath.com/news/directrx-pharmacy-distributing-copd-therapy-ohtuvayre-in-us 2024-09-09T17:53:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/directrx-pharmacy-distributing-copd-therapy-ohtuvayre-in-us 2024-09-09T17:53:33+00:00 weekly 0.7 https://trial.medpath.com/news/biorationality-fda-clarification-provides-new-indications-and-process-change-for-biosimilars 2024-09-09T17:05:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biorationality-fda-clarification-provides-new-indications-and-process-change-for-biosimilars 2024-09-09T17:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-charm-results-highlight-potential-of-iv-glibenclamide-to-improve-independent 2024-09-09T17:04:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-charm-results-highlight-potential-of-iv-glibenclamide-to-improve-independent 2024-09-09T17:04:56+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-hope-udaily-university-of-delaware 2024-09-09T16:54:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancing-hope-udaily-university-of-delaware 2024-09-09T16:54:13+00:00 weekly 0.7 https://trial.medpath.com/news/rdca-dap-nets-new-data-to-speed-research-therapies-for-cf-cystic-fibrosis-news-today 2024-09-09T16:42:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rdca-dap-nets-new-data-to-speed-research-therapies-for-cf-cystic-fibrosis-news-today 2024-09-09T16:42:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-letter-supports-use-of-new-alpha-synuclein-assay-in-trials-parkinson-s-news-today 2024-09-09T16:42:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-letter-supports-use-of-new-alpha-synuclein-assay-in-trials-parkinson-s-news-today 2024-09-09T16:42:41+00:00 weekly 0.7 https://trial.medpath.com/news/iu-research-targets-debilitating-side-effects-for-black-breast-cancer-patients 2024-09-09T16:27:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iu-research-targets-debilitating-side-effects-for-black-breast-cancer-patients 2024-09-09T16:27:22+00:00 weekly 0.7 https://trial.medpath.com/news/a-better-fix-for-food-allergies-the-atlantic 2024-09-09T15:31:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-better-fix-for-food-allergies-the-atlantic 2024-09-09T15:31:24+00:00 weekly 0.7 https://trial.medpath.com/news/pierre-fabre-laboratories-receives-european-commission-approval-for-braftovi 2024-09-09T15:31:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pierre-fabre-laboratories-receives-european-commission-approval-for-braftovi 2024-09-09T15:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/zealand-pharma-announces-positive-topline-results-from-13-week-phase-1b-multiple-quantisnow 2024-09-09T15:21:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zealand-pharma-announces-positive-topline-results-from-13-week-phase-1b-multiple-quantisnow 2024-09-09T15:21:20+00:00 weekly 0.7 https://trial.medpath.com/news/early-metabolic-profiling-could-identify-babies-at-risk-of-sids-inside-precision-medicine 2024-09-09T15:04:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-metabolic-profiling-could-identify-babies-at-risk-of-sids-inside-precision-medicine 2024-09-09T15:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/the-highly-anticipated-fda-approvals-of-galderma-s-nemolizumab-and-eli-lilly-s-markets-insider 2024-09-09T14:55:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-highly-anticipated-fda-approvals-of-galderma-s-nemolizumab-and-eli-lilly-s-markets-insider 2024-09-09T14:55:55+00:00 weekly 0.7 https://trial.medpath.com/news/a-diagnosis-of-triple-negative-breast-cancer-was-not-on-my-radar-the-asco-post 2024-09-09T14:51:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-diagnosis-of-triple-negative-breast-cancer-was-not-on-my-radar-the-asco-post 2024-09-09T14:51:50+00:00 weekly 0.7 https://trial.medpath.com/news/dow-jones-today-major-indexes-higher-as-stocks-look-to-rebound-from-biggest-weekly 2024-09-09T14:51:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dow-jones-today-major-indexes-higher-as-stocks-look-to-rebound-from-biggest-weekly 2024-09-09T14:51:29+00:00 weekly 0.7 https://trial.medpath.com/news/grail-s-potential-turnaround-seeking-fda-approval-for-galleri-nasdaq-gral 2024-09-09T14:51:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grail-s-potential-turnaround-seeking-fda-approval-for-galleri-nasdaq-gral 2024-09-09T14:51:06+00:00 weekly 0.7 https://trial.medpath.com/news/tubeless-insulin-patch-pump-receives-fda-clearance-for-type-1-and-type-2-diabetes-healio 2024-09-09T14:48:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tubeless-insulin-patch-pump-receives-fda-clearance-for-type-1-and-type-2-diabetes-healio 2024-09-09T14:48:54+00:00 weekly 0.7 https://trial.medpath.com/news/zeroing-in-on-vaginal-microbes-that-most-increase-hiv-risk-fred-hutchinson-cancer-center 2024-09-09T14:45:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zeroing-in-on-vaginal-microbes-that-most-increase-hiv-risk-fred-hutchinson-cancer-center 2024-09-09T14:45:32+00:00 weekly 0.7 https://trial.medpath.com/news/earnings-call-genus-reports-progress-amid-market-challenges-eyes-fda-approval 2024-09-09T14:27:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earnings-call-genus-reports-progress-amid-market-challenges-eyes-fda-approval 2024-09-09T14:27:26+00:00 weekly 0.7 https://trial.medpath.com/news/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical 2024-09-09T14:25:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avacta-to-present-updated-clinical-data-on-ava6000-at-the-european-society-for-medical 2024-09-09T14:25:23+00:00 weekly 0.7 https://trial.medpath.com/news/psyence-biomed-announces-initiation-of-first-trial-site-in-australia-for-its-phase-iib-study-of 2024-09-09T14:19:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psyence-biomed-announces-initiation-of-first-trial-site-in-australia-for-its-phase-iib-study-of 2024-09-09T14:19:22+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-medical-trial-for-treatment-of-hydrocephalus-to-lead-to-safer-outcomes-for-patients 2024-09-09T14:18:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovative-medical-trial-for-treatment-of-hydrocephalus-to-lead-to-safer-outcomes-for-patients 2024-09-09T14:18:44+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-study-finds-radiation-alone-may-be-as-effective-as-chemoradiation-in-patients 2024-09-09T14:08:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chinese-study-finds-radiation-alone-may-be-as-effective-as-chemoradiation-in-patients 2024-09-09T14:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-promising-biomarker-data-and-phase-iii-trials-buy-rating-affirmed 2024-09-09T14:01:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-promising-biomarker-data-and-phase-iii-trials-buy-rating-affirmed 2024-09-09T14:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/ruxolitinib-may-be-effective-in-refractory-chronic-gvhd-hematology-advisor 2024-09-09T13:49:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ruxolitinib-may-be-effective-in-refractory-chronic-gvhd-hematology-advisor 2024-09-09T13:49:19+00:00 weekly 0.7 https://trial.medpath.com/news/bambusa-therapeutics-inc-announces-successful-series-seed-funding-to-advance-morningstar 2024-09-09T13:34:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bambusa-therapeutics-inc-announces-successful-series-seed-funding-to-advance-morningstar 2024-09-09T13:34:09+00:00 weekly 0.7 https://trial.medpath.com/news/actuate-therapeutics-obtains-complete-responses-and-provides-update-on-clinical-trial-of 2024-09-09T13:34:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/actuate-therapeutics-obtains-complete-responses-and-provides-update-on-clinical-trial-of 2024-09-09T13:34:05+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-pharmaceuticals-to-present-advancements-in-solid-tumor-oncology-research-at-esmo-2024 2024-09-09T13:33:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-to-present-advancements-in-solid-tumor-oncology-research-at-esmo-2024 2024-09-09T13:33:39+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-ongoing-for-asf-bird-flu-vaccines-businessworld-online 2024-09-09T13:32:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-ongoing-for-asf-bird-flu-vaccines-businessworld-online 2024-09-09T13:32:58+00:00 weekly 0.7 https://trial.medpath.com/news/candid-with-370m-sets-out-to-prove-bispecifics-worth-in-autoimmune-disease 2024-09-09T13:26:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/candid-with-370m-sets-out-to-prove-bispecifics-worth-in-autoimmune-disease 2024-09-09T13:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/rytelotm-imetelstat-fda-approved-for-treatment-of-patients-with-low-to-intermediate-1 2024-09-09T13:25:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rytelotm-imetelstat-fda-approved-for-treatment-of-patients-with-low-to-intermediate-1 2024-09-09T13:25:16+00:00 weekly 0.7 https://trial.medpath.com/news/t2-biosystems-provides-updates-on-its-new-product-development-pipeline-progress 2024-09-09T13:25:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/t2-biosystems-provides-updates-on-its-new-product-development-pipeline-progress 2024-09-09T13:25:10+00:00 weekly 0.7 https://trial.medpath.com/news/china-s-akeso-soars-after-new-cancer-drug-beats-market-leader-in-clinical-trials 2024-09-09T13:18:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-s-akeso-soars-after-new-cancer-drug-beats-market-leader-in-clinical-trials 2024-09-09T13:18:26+00:00 weekly 0.7 https://trial.medpath.com/news/femasys-inc-receives-u-s-fda-clearance-to-market-femchec-r-an-innovative-diagnostic 2024-09-09T13:14:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/femasys-inc-receives-u-s-fda-clearance-to-market-femchec-r-an-innovative-diagnostic 2024-09-09T13:14:31+00:00 weekly 0.7 https://trial.medpath.com/news/epsilogen-ltd-completes-ps12-5m-series-b-expansion-european-biotechnology-magazine 2024-09-09T13:14:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/epsilogen-ltd-completes-ps12-5m-series-b-expansion-european-biotechnology-magazine 2024-09-09T13:14:30+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-presents-new-data-for-first-in-class-imdelltratm-tarlatamab 2024-09-09T13:06:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-presents-new-data-for-first-in-class-imdelltratm-tarlatamab 2024-09-09T13:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/evaxion-reports-69-overall-response-rate-in-its-phase-2-trial-on-lead-cancer-vaccine 2024-09-09T13:04:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaxion-reports-69-overall-response-rate-in-its-phase-2-trial-on-lead-cancer-vaccine 2024-09-09T13:04:00+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-showcases-advancement-of-solid-tumor-pipeline-at-esmo-2024-with-new-data-in 2024-09-09T13:02:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-showcases-advancement-of-solid-tumor-pipeline-at-esmo-2024-with-new-data-in 2024-09-09T13:02:58+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-monkeypox-vaccine-gets-green-light-for-clinical-trials-chinadaily-com-cn 2024-09-09T13:01:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chinese-monkeypox-vaccine-gets-green-light-for-clinical-trials-chinadaily-com-cn 2024-09-09T13:01:20+00:00 weekly 0.7 https://trial.medpath.com/news/september-2024-letter-to-shareholders-cytodyn-inc 2024-09-09T12:35:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/september-2024-letter-to-shareholders-cytodyn-inc 2024-09-09T12:35:02+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-to-present-updated-versatile-002-data-at-esmo-congress-2024 2024-09-09T12:34:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotech-to-present-updated-versatile-002-data-at-esmo-congress-2024 2024-09-09T12:34:03+00:00 weekly 0.7 https://trial.medpath.com/news/biostock-has-published-an-article-on-the-approved-ompd-for-cs1-in-the-eu-marketscreener 2024-09-09T12:28:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biostock-has-published-an-article-on-the-approved-ompd-for-cs1-in-the-eu-marketscreener 2024-09-09T12:28:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-illumina-cancer-biomarker-test-san-diego-business-journal 2024-09-09T12:28:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-illumina-cancer-biomarker-test-san-diego-business-journal 2024-09-09T12:28:18+00:00 weekly 0.7 https://trial.medpath.com/news/data-show-sustained-benefits-of-deucrictibant-for-hae-attacks-angioedema-news 2024-09-09T12:22:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-show-sustained-benefits-of-deucrictibant-for-hae-attacks-angioedema-news 2024-09-09T12:22:54+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-will-test-obesity-drug-maritide-for-kidney-and-other-diseases-docwire-news 2024-09-09T12:21:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-will-test-obesity-drug-maritide-for-kidney-and-other-diseases-docwire-news 2024-09-09T12:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-announces-first-patients-treated-in-phase-2-clinical-trial-of-stat3-stock-titan 2024-09-09T12:20:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moleculin-announces-first-patients-treated-in-phase-2-clinical-trial-of-stat3-stock-titan 2024-09-09T12:20:26+00:00 weekly 0.7 https://trial.medpath.com/news/agilent-unveils-biopharma-cdx-services-lab-to-accelerate-precision-medicine-stock-titan 2024-09-09T12:20:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/agilent-unveils-biopharma-cdx-services-lab-to-accelerate-precision-medicine-stock-titan 2024-09-09T12:20:24+00:00 weekly 0.7 https://trial.medpath.com/news/ub-professor-nys-researchers-developing-immunotherapy-treatment-for-alzheimer-s 2024-09-09T12:14:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ub-professor-nys-researchers-developing-immunotherapy-treatment-for-alzheimer-s 2024-09-09T12:14:32+00:00 weekly 0.7 https://trial.medpath.com/news/phase-i-study-of-safety-and-efficacy-of-allogeneic-natural-killer-cell-therapy-in-relapsed 2024-09-09T12:08:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-i-study-of-safety-and-efficacy-of-allogeneic-natural-killer-cell-therapy-in-relapsed 2024-09-09T12:08:45+00:00 weekly 0.7 https://trial.medpath.com/news/annexon-to-present-phase-2-archer-data-on-protection-of-vision-and-photoreceptors-with 2024-09-09T12:06:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/annexon-to-present-phase-2-archer-data-on-protection-of-vision-and-photoreceptors-with 2024-09-09T12:06:09+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-announces-positive-pre-bla-meeting-with-fda-and-globenewswire 2024-09-09T12:04:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-announces-positive-pre-bla-meeting-with-fda-and-globenewswire 2024-09-09T12:04:09+00:00 weekly 0.7 https://trial.medpath.com/news/rezolute-s-rz358-advances-with-fda-clearance-for-study-tipranks-com 2024-09-09T11:59:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rezolute-s-rz358-advances-with-fda-clearance-for-study-tipranks-com 2024-09-09T11:59:17+00:00 weekly 0.7 https://trial.medpath.com/news/medicenna-presents-preclinical-results-from-its-il-2-super-antagonist-and-anti-pd1-il-2 2024-09-09T11:59:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicenna-presents-preclinical-results-from-its-il-2-super-antagonist-and-anti-pd1-il-2 2024-09-09T11:59:08+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-presented-data-on-the-potential-mpox-vaccine-tnx-801-in-morningstar 2024-09-09T11:35:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-presented-data-on-the-potential-mpox-vaccine-tnx-801-in-morningstar 2024-09-09T11:35:59+00:00 weekly 0.7 https://trial.medpath.com/news/terns-pharmaceuticals-announces-positive-phase-1-clinical-trial-results-with-tern-601 2024-09-09T11:35:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/terns-pharmaceuticals-announces-positive-phase-1-clinical-trial-results-with-tern-601 2024-09-09T11:35:57+00:00 weekly 0.7 https://trial.medpath.com/news/cartesian-therapeutics-receives-fda-rare-pediatric-disease-designation-for-descartes-08 2024-09-09T11:18:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cartesian-therapeutics-receives-fda-rare-pediatric-disease-designation-for-descartes-08 2024-09-09T11:18:14+00:00 weekly 0.7 https://trial.medpath.com/news/sab-bio-provides-sab-142-clinical-trial-progress-update-at-the-european-association-for 2024-09-09T11:13:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sab-bio-provides-sab-142-clinical-trial-progress-update-at-the-european-association-for 2024-09-09T11:13:00+00:00 weekly 0.7 https://trial.medpath.com/news/akero-therapeutics-announces-first-patient-dosed-in-phase-3-synchrony-outcomes 2024-09-09T11:04:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akero-therapeutics-announces-first-patient-dosed-in-phase-3-synchrony-outcomes 2024-09-09T11:04:11+00:00 weekly 0.7 https://trial.medpath.com/news/targeting-the-racial-disparity-in-kidney-disease 2024-09-09T11:00:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targeting-the-racial-disparity-in-kidney-disease 2024-09-09T11:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/1104-tackling-the-root-cause-of-allergic-disease-drug-target-review 2024-09-09T10:58:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/1104-tackling-the-root-cause-of-allergic-disease-drug-target-review 2024-09-09T10:58:08+00:00 weekly 0.7 https://trial.medpath.com/news/dr-sen-on-interim-ideate-lung01-data-in-extensive-stage-sclc-onclive 2024-09-09T10:47:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-sen-on-interim-ideate-lung01-data-in-extensive-stage-sclc-onclive 2024-09-09T10:47:13+00:00 weekly 0.7 https://trial.medpath.com/news/fosun-pharma-s-new-drug-wins-approval-tipranks-com 2024-09-09T10:41:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fosun-pharma-s-new-drug-wins-approval-tipranks-com 2024-09-09T10:41:09+00:00 weekly 0.7 https://trial.medpath.com/news/u-ploid-announces-breakthrough-technology-to-overcome-age-related-infertility 2024-09-09T10:23:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-ploid-announces-breakthrough-technology-to-overcome-age-related-infertility 2024-09-09T10:23:17+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-receives-ema-approval-marketscreener 2024-09-09T10:16:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-receives-ema-approval-marketscreener 2024-09-09T10:16:03+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-completes-clinical-trials-for-near-zero-emission-inhalers-businessgreen-news 2024-09-09T09:11:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-completes-clinical-trials-for-near-zero-emission-inhalers-businessgreen-news 2024-09-09T09:11:18+00:00 weekly 0.7 https://trial.medpath.com/news/immunovant-provides-update-on-graves-disease-development-program-biospace 2024-09-09T09:09:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunovant-provides-update-on-graves-disease-development-program-biospace 2024-09-09T09:09:11+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-leklaza-combination-therapy-what-are-the-prospects-for-monotherapy-in 2024-09-09T08:50:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-leklaza-combination-therapy-what-are-the-prospects-for-monotherapy-in 2024-09-09T08:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/tilt-biotherapeutics-presents-clinical-data-on-tilt-123-globenewswire 2024-09-09T07:03:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tilt-biotherapeutics-presents-clinical-data-on-tilt-123-globenewswire 2024-09-09T07:03:14+00:00 weekly 0.7 https://trial.medpath.com/news/annual-mammograms-show-superior-outcomes-in-breast-cancer-detection-and-survival-rates 2024-09-09T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/annual-mammograms-show-superior-outcomes-in-breast-cancer-detection-and-survival-rates 2024-09-09T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine 2024-09-09T06:57:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine 2024-09-09T06:57:57+00:00 weekly 0.7 https://trial.medpath.com/news/myongji-hospital-develops-tool-to-predict-ovarian-cancer-drug-resistance-hospital-article-kbr 2024-09-09T06:47:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/myongji-hospital-develops-tool-to-predict-ovarian-cancer-drug-resistance-hospital-article-kbr 2024-09-09T06:47:34+00:00 weekly 0.7 https://trial.medpath.com/news/cizzle-biotechnology-collaborates-with-moffitt-cancer-center-directorstalk-interviews 2024-09-09T06:38:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cizzle-biotechnology-collaborates-with-moffitt-cancer-center-directorstalk-interviews 2024-09-09T06:38:48+00:00 weekly 0.7 https://trial.medpath.com/news/chugai-seeks-additional-indication-approval-from-japan-mhlw-for-vabysmo-to-treat-angioid 2024-09-09T06:30:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chugai-seeks-additional-indication-approval-from-japan-mhlw-for-vabysmo-to-treat-angioid 2024-09-09T06:30:50+00:00 weekly 0.7 https://trial.medpath.com/news/hemogenyx-pharmaceuticals-plc-flt3-assay-ready-for-phase-i-trials-at-md-anderson 2024-09-09T06:28:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hemogenyx-pharmaceuticals-plc-flt3-assay-ready-for-phase-i-trials-at-md-anderson 2024-09-09T06:28:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-oral-jak-inhibitors-show-promise-in-treating-moderate-to-severe-atopic-dermatitis 2024-09-09T05:17:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approved-oral-jak-inhibitors-show-promise-in-treating-moderate-to-severe-atopic-dermatitis 2024-09-09T05:17:03+00:00 weekly 0.7 https://trial.medpath.com/news/global-biopharmaceutical-innovator-pharmaessentia-launches-new 2024-09-09T05:15:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-biopharmaceutical-innovator-pharmaessentia-launches-new 2024-09-09T05:15:38+00:00 weekly 0.7 https://trial.medpath.com/news/innate-pharma-sa-monalizumab-data-from-neocoast-2-phase-2-study-in-early-stage 2024-09-09T05:08:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innate-pharma-sa-monalizumab-data-from-neocoast-2-phase-2-study-in-early-stage 2024-09-09T05:08:28+00:00 weekly 0.7 https://trial.medpath.com/news/poltreg-treg-cell-therapy-for-patients-with-type-1-diabetes-globenewswire 2024-09-09T05:02:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poltreg-treg-cell-therapy-for-patients-with-type-1-diabetes-globenewswire 2024-09-09T05:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/late-stage-alzheimer-s-pipeline-goes-beyond-amyloid-and-tau-biospace 2024-09-09T04:10:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/late-stage-alzheimer-s-pipeline-goes-beyond-amyloid-and-tau-biospace 2024-09-09T04:10:58+00:00 weekly 0.7 https://trial.medpath.com/news/mda-kickstart-program-launches-for-ultra-rare-neuromuscular-disease-drug-development 2024-09-09T04:01:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mda-kickstart-program-launches-for-ultra-rare-neuromuscular-disease-drug-development 2024-09-09T04:01:41+00:00 weekly 0.7 https://trial.medpath.com/news/healios-kk-advances-global-phase-3-ards-trial-tipranks-com 2024-09-09T03:58:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/healios-kk-advances-global-phase-3-ards-trial-tipranks-com 2024-09-09T03:58:53+00:00 weekly 0.7 https://trial.medpath.com/news/br-6002-by-boryung-pharmaceutical-for-cardiovascular-disease-likelihood-of-approval 2024-09-09T03:09:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/br-6002-by-boryung-pharmaceutical-for-cardiovascular-disease-likelihood-of-approval 2024-09-09T03:09:14+00:00 weekly 0.7 https://trial.medpath.com/news/senhwa-biosciences-presents-clinical-data-abstract-on-pidnarulex-at-2024-esmo-congress 2024-09-09T02:39:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/senhwa-biosciences-presents-clinical-data-abstract-on-pidnarulex-at-2024-esmo-congress 2024-09-09T02:39:41+00:00 weekly 0.7 https://trial.medpath.com/news/hutchmed-highlights-clinical-data-to-be-presented-at-esmo-congress-2024-and-the 2024-09-09T01:53:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hutchmed-highlights-clinical-data-to-be-presented-at-esmo-congress-2024-and-the 2024-09-09T01:53:41+00:00 weekly 0.7 https://trial.medpath.com/news/antennova-to-present-latest-data-of-atn-037-in-a-mini-oral-presentation-at-esmo-congress-2024 2024-09-09T00:52:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antennova-to-present-latest-data-of-atn-037-in-a-mini-oral-presentation-at-esmo-congress-2024 2024-09-09T00:52:39+00:00 weekly 0.7 https://trial.medpath.com/news/natera-to-present-new-signateratm-colorectal-cancer-data-at-esmo-showing-10x 2024-09-09T00:34:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/natera-to-present-new-signateratm-colorectal-cancer-data-at-esmo-showing-10x 2024-09-09T00:34:38+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-s-foscenvivint-shows-promise-in-pancreatic-cancer-development-pipeline 2024-09-09T00:12:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-s-foscenvivint-shows-promise-in-pancreatic-cancer-development-pipeline 2024-09-09T00:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/alfasigma-advances-filgotinib-maleate-development-for-igg4-related-disease-treatment 2024-09-09T00:03:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alfasigma-advances-filgotinib-maleate-development-for-igg4-related-disease-treatment 2024-09-09T00:03:06+00:00 weekly 0.7 https://trial.medpath.com/news/update-imunons-ovarian-cancer-r-d-day-to-feature-presentations-from-imnn-001-clinical-study-investigators-immunology-and-biostatistics-experts-and-executive-management 2024-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/update-imunons-ovarian-cancer-r-d-day-to-feature-presentations-from-imnn-001-clinical-study-investigators-immunology-and-biostatistics-experts-and-executive-management 2024-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakwater-study-shows-promise-for-encorafenib-cetuximab-plus-folfiri-in-braf-v600e-mutant-colorectal-cancer 2024-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakwater-study-shows-promise-for-encorafenib-cetuximab-plus-folfiri-in-braf-v600e-mutant-colorectal-cancer 2024-09-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hr20013-demonstrates-noninferiority-in-preventing-chemo-induced-nausea-vomiting 2024-09-08T23:26:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hr20013-demonstrates-noninferiority-in-preventing-chemo-induced-nausea-vomiting 2024-09-08T23:26:15+00:00 weekly 0.7 https://trial.medpath.com/news/lecanemab-the-drug-giving-hope-to-people-at-risk-of-dementia-hmri 2024-09-08T23:25:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lecanemab-the-drug-giving-hope-to-people-at-risk-of-dementia-hmri 2024-09-08T23:25:01+00:00 weekly 0.7 https://trial.medpath.com/news/anti-pd-l1-antibody-asc22-in-combination-with-a-histone-deacetylase-inhibitor-chidamide-nature 2024-09-08T23:16:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anti-pd-l1-antibody-asc22-in-combination-with-a-histone-deacetylase-inhibitor-chidamide-nature 2024-09-08T23:16:58+00:00 weekly 0.7 https://trial.medpath.com/news/macrogenics-announces-tamarack-phase-2-data-presentation-at-esmo-congress-2024 2024-09-08T23:15:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/macrogenics-announces-tamarack-phase-2-data-presentation-at-esmo-congress-2024 2024-09-08T23:15:07+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-combining-durvalumab-with-novel-agents-increases-pathological-responses-in 2024-09-08T23:10:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-combining-durvalumab-with-novel-agents-increases-pathological-responses-in 2024-09-08T23:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/cantargia-new-data-from-two-clinical-studies-strongly-support-nadunolimab-efficacy-after 2024-09-08T22:21:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cantargia-new-data-from-two-clinical-studies-strongly-support-nadunolimab-efficacy-after 2024-09-08T22:21:33+00:00 weekly 0.7 https://trial.medpath.com/news/ultimovacs-announces-updated-data-analysis-on-uv1-phase-ii-globenewswire 2024-09-08T22:18:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultimovacs-announces-updated-data-analysis-on-uv1-phase-ii-globenewswire 2024-09-08T22:18:22+00:00 weekly 0.7 https://trial.medpath.com/news/c4-therapeutics-to-present-preliminary-cft1946-monotherapy-phase-1-clinical-data-at-the 2024-09-08T22:12:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/c4-therapeutics-to-present-preliminary-cft1946-monotherapy-phase-1-clinical-data-at-the 2024-09-08T22:12:22+00:00 weekly 0.7 https://trial.medpath.com/news/summit-lung-cancer-drug-shows-striking-benefit-over-keytruda-biopharma-dive 2024-09-08T22:10:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/summit-lung-cancer-drug-shows-striking-benefit-over-keytruda-biopharma-dive 2024-09-08T22:10:49+00:00 weekly 0.7 https://trial.medpath.com/news/dr-spira-on-updated-mariposa-trial-data-in-egfr-advanced-nsclc-onclive 2024-09-08T22:07:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-spira-on-updated-mariposa-trial-data-in-egfr-advanced-nsclc-onclive 2024-09-08T22:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/a-biotech-going-through-the-nose-to-treat-the-brain-plots-alternative-path-to-public-markets 2024-09-08T21:52:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-biotech-going-through-the-nose-to-treat-the-brain-plots-alternative-path-to-public-markets 2024-09-08T21:52:34+00:00 weekly 0.7 https://trial.medpath.com/news/durvalumab-combo-maintains-pfs-benefit-in-ovarian-cancer-targeted-oncology 2024-09-08T21:04:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/durvalumab-combo-maintains-pfs-benefit-in-ovarian-cancer-targeted-oncology 2024-09-08T21:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/effectiveness-of-structured-multidisciplinary-long-term-care-for-pediatric-cancer-survivors 2024-09-08T20:32:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effectiveness-of-structured-multidisciplinary-long-term-care-for-pediatric-cancer-survivors 2024-09-08T20:32:05+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-ii-trial-examining-the-safety-and-preliminary-efficacy-of-repetitive-transcranial 2024-09-08T20:30:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-phase-ii-trial-examining-the-safety-and-preliminary-efficacy-of-repetitive-transcranial 2024-09-08T20:30:06+00:00 weekly 0.7 https://trial.medpath.com/news/study-reports-2-year-survival-data-on-nivolumab-plus-relatlimab-in-nsclc 2024-09-08T19:22:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reports-2-year-survival-data-on-nivolumab-plus-relatlimab-in-nsclc 2024-09-08T19:22:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-oked-new-drug-application-for-novel-glioblastoma-treatment-cure-today 2024-09-08T19:10:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-oked-new-drug-application-for-novel-glioblastoma-treatment-cure-today 2024-09-08T19:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/research-identifies-potential-biomarkers-for-treatment-response-in-psa-hcplive 2024-09-08T18:31:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-identifies-potential-biomarkers-for-treatment-response-in-psa-hcplive 2024-09-08T18:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/sun-pharma-s-sonidegib-shows-promise-across-multiple-cancer-indications-beyond-basal-cell-carcinoma 2024-09-08T18:28:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sun-pharma-s-sonidegib-shows-promise-across-multiple-cancer-indications-beyond-basal-cell-carcinoma 2024-09-08T18:28:51+00:00 weekly 0.7 https://trial.medpath.com/news/minovia-s-mnv-201-cell-therapy-shows-promise-for-rare-pearson-syndrome-treatment 2024-09-08T18:26:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/minovia-s-mnv-201-cell-therapy-shows-promise-for-rare-pearson-syndrome-treatment 2024-09-08T18:26:19+00:00 weekly 0.7 https://trial.medpath.com/news/first-in-class-cebranopadol-moving-to-phase-3-trials-managed-healthcare-executive 2024-09-08T18:14:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-in-class-cebranopadol-moving-to-phase-3-trials-managed-healthcare-executive 2024-09-08T18:14:14+00:00 weekly 0.7 https://trial.medpath.com/news/emicizumab-shows-promise-for-acquired-hemophilia-a-treatment-in-development-pipeline 2024-09-08T17:57:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emicizumab-shows-promise-for-acquired-hemophilia-a-treatment-in-development-pipeline 2024-09-08T17:57:42+00:00 weekly 0.7 https://trial.medpath.com/news/rybrevant-r-amivantamab-vmjw-plus-lazcluzetm-lazertinib-show-strong-favorable 2024-09-08T17:49:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rybrevant-r-amivantamab-vmjw-plus-lazcluzetm-lazertinib-show-strong-favorable 2024-09-08T17:49:14+00:00 weekly 0.7 https://trial.medpath.com/news/risk-adjusted-net-present-value-what-is-the-current-valuation-of-deciphera 2024-09-08T17:45:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/risk-adjusted-net-present-value-what-is-the-current-valuation-of-deciphera 2024-09-08T17:45:12+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-nivolumab-may-bolster-survival-over-only-neoadjuvant-nivolumab-plus 2024-09-08T17:18:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perioperative-nivolumab-may-bolster-survival-over-only-neoadjuvant-nivolumab-plus 2024-09-08T17:18:32+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-before-and-after-lung-cancer-surgery-reduces-death-risk-and-disease 2024-09-08T17:12:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-before-and-after-lung-cancer-surgery-reduces-death-risk-and-disease 2024-09-08T17:12:44+00:00 weekly 0.7 https://trial.medpath.com/news/il-21-promises-to-revolutionize-treatment-for-glioblastoma-pembrolizumab-trials-halted-in 2024-09-08T17:03:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/il-21-promises-to-revolutionize-treatment-for-glioblastoma-pembrolizumab-trials-halted-in 2024-09-08T17:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/novel-computational-pathology-based-trop2-biomarker-for-datopotamab-deruxtecan-was 2024-09-08T16:36:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-computational-pathology-based-trop2-biomarker-for-datopotamab-deruxtecan-was 2024-09-08T16:36:17+00:00 weekly 0.7 https://trial.medpath.com/news/global-experts-share-strategies-to-enhance-lung-cancer-screening-access-and-early-detection 2024-09-08T16:30:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-experts-share-strategies-to-enhance-lung-cancer-screening-access-and-early-detection 2024-09-08T16:30:45+00:00 weekly 0.7 https://trial.medpath.com/news/ivonescimab-monotherapy-reduced-the-risk-of-disease-progression-or-death-by-49-morningstar 2024-09-08T16:03:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ivonescimab-monotherapy-reduced-the-risk-of-disease-progression-or-death-by-49-morningstar 2024-09-08T16:03:05+00:00 weekly 0.7 https://trial.medpath.com/news/company-announcement-markets-data 2024-09-08T15:49:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/company-announcement-markets-data 2024-09-08T15:49:26+00:00 weekly 0.7 https://trial.medpath.com/news/association-of-leucine-and-other-branched-chain-amino-acids-with-clinical-outcomes-in-nature 2024-09-08T14:58:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/association-of-leucine-and-other-branched-chain-amino-acids-with-clinical-outcomes-in-nature 2024-09-08T14:58:15+00:00 weekly 0.7 https://trial.medpath.com/news/vaxcyte-s-broad-spectrum-pneumococcal-vaccines-poised-for-market-dominance-by-2027 2024-09-08T14:34:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vaxcyte-s-broad-spectrum-pneumococcal-vaccines-poised-for-market-dominance-by-2027 2024-09-08T14:34:14+00:00 weekly 0.7 https://trial.medpath.com/news/lower-risk-mds-population-has-enduring-rbc-ti-following-imetelstat-therapy 2024-09-08T14:09:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lower-risk-mds-population-has-enduring-rbc-ti-following-imetelstat-therapy 2024-09-08T14:09:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-think-surgical-robotic-system-for-use-with-medacta-knee-implants-healio 2024-09-08T13:57:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-think-surgical-robotic-system-for-use-with-medacta-knee-implants-healio 2024-09-08T13:57:39+00:00 weekly 0.7 https://trial.medpath.com/news/childhood-antibioticination-reduces-mortality-in-africa-contagion-live 2024-09-08T13:26:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/childhood-antibioticination-reduces-mortality-in-africa-contagion-live 2024-09-08T13:26:31+00:00 weekly 0.7 https://trial.medpath.com/news/revealed-the-bowel-cancer-breakthrough-that-could-save-young-sufferers-daily-mail 2024-09-08T13:12:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revealed-the-bowel-cancer-breakthrough-that-could-save-young-sufferers-daily-mail 2024-09-08T13:12:44+00:00 weekly 0.7 https://trial.medpath.com/news/all-about-cholesterol-american-society-for-biochemistry-and-molecular-biology 2024-09-08T12:15:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/all-about-cholesterol-american-society-for-biochemistry-and-molecular-biology 2024-09-08T12:15:17+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drug-leqembi-promises-to-give-patients-more-time-but-they-face-a-long-road-to-treatment 2024-09-08T12:03:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-drug-leqembi-promises-to-give-patients-more-time-but-they-face-a-long-road-to-treatment 2024-09-08T12:03:19+00:00 weekly 0.7 https://trial.medpath.com/news/longboard-pharmaceuticals-announces-positive-interim-analysis-results-from-the-stock-titan 2024-09-08T11:35:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longboard-pharmaceuticals-announces-positive-interim-analysis-results-from-the-stock-titan 2024-09-08T11:35:43+00:00 weekly 0.7 https://trial.medpath.com/news/ai-platform-demonstrates-promising-results-in-treating-patient-with-rare-cancer 2024-09-08T11:31:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-platform-demonstrates-promising-results-in-treating-patient-with-rare-cancer 2024-09-08T11:31:44+00:00 weekly 0.7 https://trial.medpath.com/news/savara-announces-new-data-from-pivotal-phase-3-impala-2-trial-of-molgramostim-morningstar 2024-09-08T11:02:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/savara-announces-new-data-from-pivotal-phase-3-impala-2-trial-of-molgramostim-morningstar 2024-09-08T11:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/celcuity-s-gedatolisib-projected-to-reach-155m-annual-revenue-by-2034-for-breast-cancer-treatment 2024-09-08T09:14:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/celcuity-s-gedatolisib-projected-to-reach-155m-annual-revenue-by-2034-for-breast-cancer-treatment 2024-09-08T09:14:13+00:00 weekly 0.7 https://trial.medpath.com/news/tenaya-therapeutics-gene-therapy-tn-201-shows-promise-with-projected-165m-revenue-for-cardiomyopathy-treatment 2024-09-08T09:13:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tenaya-therapeutics-gene-therapy-tn-201-shows-promise-with-projected-165m-revenue-for-cardiomyopathy-treatment 2024-09-08T09:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-s-myk-224-for-hypertrophic-cardiomyopathy-projects-41m-revenue-by-2035 2024-09-08T09:11:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-s-myk-224-for-hypertrophic-cardiomyopathy-projects-41m-revenue-by-2035 2024-09-08T09:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/regulus-therapeutics-rgls-8429-projected-to-reach-213m-annual-revenue-by-2037-for-adpkd-treatment 2024-09-08T09:10:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regulus-therapeutics-rgls-8429-projected-to-reach-213m-annual-revenue-by-2037-for-adpkd-treatment 2024-09-08T09:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/jcr-pharmaceuticals-laronidase-for-hurler-syndrome-expected-to-generate-38m-by-2040 2024-09-08T09:08:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jcr-pharmaceuticals-laronidase-for-hurler-syndrome-expected-to-generate-38m-by-2040 2024-09-08T09:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/iteos-therapeutics-tigit-inhibitor-belrestotug-projects-366m-peak-revenue-for-solid-tumors-by-2038 2024-09-08T09:06:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iteos-therapeutics-tigit-inhibitor-belrestotug-projects-366m-peak-revenue-for-solid-tumors-by-2038 2024-09-08T09:06:16+00:00 weekly 0.7 https://trial.medpath.com/news/insmed-s-treprostinil-palmitil-shows-promise-for-rare-pulmonary-disorders-with-projected-66m-revenue-by-2037 2024-09-08T09:05:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insmed-s-treprostinil-palmitil-shows-promise-for-rare-pulmonary-disorders-with-projected-66m-revenue-by-2037 2024-09-08T09:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/altimmune-s-pemvidutide-projected-to-reach-759m-in-global-sales-by-2039 2024-09-08T09:03:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/altimmune-s-pemvidutide-projected-to-reach-759m-in-global-sales-by-2039 2024-09-08T09:03:31+00:00 weekly 0.7 https://trial.medpath.com/news/dupilumab-treatment-effective-for-chronic-rhinosinusitis-with-nasal-polyps-hcplive 2024-09-08T08:42:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dupilumab-treatment-effective-for-chronic-rhinosinusitis-with-nasal-polyps-hcplive 2024-09-08T08:42:07+00:00 weekly 0.7 https://trial.medpath.com/news/beigene-s-bgb-16673-shows-promise-in-blood-cancer-treatment-with-projected-9m-revenue-by-2037 2024-09-08T08:39:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beigene-s-bgb-16673-shows-promise-in-blood-cancer-treatment-with-projected-9m-revenue-by-2037 2024-09-08T08:39:51+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-s-maridebart-cafraglutide-projected-to-reach-527-million-in-us-sales-by-2039 2024-09-08T08:33:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-s-maridebart-cafraglutide-projected-to-reach-527-million-in-us-sales-by-2039 2024-09-08T08:33:30+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-s-atrasentan-shows-promise-with-projected-229m-revenue-by-2033-for-kidney-diseases 2024-09-08T08:32:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-s-atrasentan-shows-promise-with-projected-229m-revenue-by-2033-for-kidney-diseases 2024-09-08T08:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-s-ide-397-shows-promise-in-multiple-solid-tumors-with-47m-revenue-projection-by-2037 2024-09-08T08:29:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-s-ide-397-shows-promise-in-multiple-solid-tumors-with-47m-revenue-projection-by-2037 2024-09-08T08:29:17+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-how-nanorobots-could-prevent-strokes-newsbytes 2024-09-08T08:24:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-shows-how-nanorobots-could-prevent-strokes-newsbytes 2024-09-08T08:24:53+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rejection-of-mdma-could-fuel-black-market-demand-warns-ceo-of-women-s 2024-09-08T08:08:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-rejection-of-mdma-could-fuel-black-market-demand-warns-ceo-of-women-s 2024-09-08T08:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/mesa-lab-testing-new-leg-wound-care-products-eastvalleytribune-com 2024-09-08T07:07:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mesa-lab-testing-new-leg-wound-care-products-eastvalleytribune-com 2024-09-08T07:07:26+00:00 weekly 0.7 https://trial.medpath.com/news/non-invasive-optoacoustic-imaging-of-glycogen-storage-and-muscle-degeneration-in-late 2024-09-08T06:45:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/non-invasive-optoacoustic-imaging-of-glycogen-storage-and-muscle-degeneration-in-late 2024-09-08T06:45:42+00:00 weekly 0.7 https://trial.medpath.com/news/spain-pharma-company-key-in-life-saving-drug-euro-weekly-news 2024-09-08T05:31:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spain-pharma-company-key-in-life-saving-drug-euro-weekly-news 2024-09-08T05:31:54+00:00 weekly 0.7 https://trial.medpath.com/news/first-comprehensive-review-of-sma-drugs-offers-long-term-insights-outcome-gaps 2024-09-08T02:49:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-comprehensive-review-of-sma-drugs-offers-long-term-insights-outcome-gaps 2024-09-08T02:49:33+00:00 weekly 0.7 https://trial.medpath.com/news/dose-justification-for-asciminib-in-patients-with-philadelphia-chromosome-positive-chronic 2024-09-08T01:39:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dose-justification-for-asciminib-in-patients-with-philadelphia-chromosome-positive-chronic 2024-09-08T01:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/levicept-levi-04-reduces-osteoarthritis-pain-2-minute-medicine 2024-09-07T23:48:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/levicept-levi-04-reduces-osteoarthritis-pain-2-minute-medicine 2024-09-07T23:48:11+00:00 weekly 0.7 https://trial.medpath.com/news/antibody-drug-conjugate-i-dxd-shows-meaningful-response-in-patients-with-extensive-stage 2024-09-07T22:18:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antibody-drug-conjugate-i-dxd-shows-meaningful-response-in-patients-with-extensive-stage 2024-09-07T22:18:04+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-hydrogel-may-cut-diabetes-shots-to-monthly-mirage-news 2024-09-07T22:03:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/semaglutide-hydrogel-may-cut-diabetes-shots-to-monthly-mirage-news 2024-09-07T22:03:23+00:00 weekly 0.7 https://trial.medpath.com/news/merck-daiichi-post-trial-data-for-lung-cancer-drug-nyse-mrk-seeking-alpha 2024-09-07T21:13:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-daiichi-post-trial-data-for-lung-cancer-drug-nyse-mrk-seeking-alpha 2024-09-07T21:13:37+00:00 weekly 0.7 https://trial.medpath.com/news/this-week-in-ophthalmology-week-of-september-1-2024 2024-09-07T21:06:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/this-week-in-ophthalmology-week-of-september-1-2024 2024-09-07T21:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/high-risk-cll-subgroups-see-benefits-with-liso-cel-targeted-oncology 2024-09-07T21:05:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-risk-cll-subgroups-see-benefits-with-liso-cel-targeted-oncology 2024-09-07T21:05:27+00:00 weekly 0.7 https://trial.medpath.com/news/tryptamine-therapeutics-sets-date-for-agm-advances-clinical-trials-tipranks-com 2024-09-07T19:24:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tryptamine-therapeutics-sets-date-for-agm-advances-clinical-trials-tipranks-com 2024-09-07T19:24:16+00:00 weekly 0.7 https://trial.medpath.com/news/recreational-drug-use-tied-to-repeat-cardiovascular-events-medical-xpress 2024-09-07T19:21:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recreational-drug-use-tied-to-repeat-cardiovascular-events-medical-xpress 2024-09-07T19:21:14+00:00 weekly 0.7 https://trial.medpath.com/news/effect-of-adding-electroacupuncture-to-standard-triple-antiemetic-therapy-on-pubmed 2024-09-07T18:49:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effect-of-adding-electroacupuncture-to-standard-triple-antiemetic-therapy-on-pubmed 2024-09-07T18:49:55+00:00 weekly 0.7 https://trial.medpath.com/news/brentuximab-vedotin-triplet-continues-to-improve-r-r-diffuse-large-b-cell-lymphoma-outcomes 2024-09-07T18:39:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brentuximab-vedotin-triplet-continues-to-improve-r-r-diffuse-large-b-cell-lymphoma-outcomes 2024-09-07T18:39:20+00:00 weekly 0.7 https://trial.medpath.com/news/multicenter-radio-multiomic-analysis-for-predicting-breast-cancer-outcome-and-unravelling 2024-09-07T18:36:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/multicenter-radio-multiomic-analysis-for-predicting-breast-cancer-outcome-and-unravelling 2024-09-07T18:36:43+00:00 weekly 0.7 https://trial.medpath.com/news/buy-rating-maintained-for-unicycive-therapeutics-amidst-olc-nda-submission-and-strong 2024-09-07T18:07:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/buy-rating-maintained-for-unicycive-therapeutics-amidst-olc-nda-submission-and-strong 2024-09-07T18:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/immunic-drug-targeting-post-covid-syndrome-in-phase-2-trial-icymi-nasdaq-imux 2024-09-07T17:16:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunic-drug-targeting-post-covid-syndrome-in-phase-2-trial-icymi-nasdaq-imux 2024-09-07T17:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/global-survey-reveals-persistent-barriers-to-lung-cancer-biomarker-testing-despite-growing-recognition 2024-09-07T17:07:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-survey-reveals-persistent-barriers-to-lung-cancer-biomarker-testing-despite-growing-recognition 2024-09-07T17:07:12+00:00 weekly 0.7 https://trial.medpath.com/news/frontline-golcadomide-r-chop-combo-elicits-antitumor-activity-in-aggressive-b-cell-lymphoma 2024-09-07T17:06:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/frontline-golcadomide-r-chop-combo-elicits-antitumor-activity-in-aggressive-b-cell-lymphoma 2024-09-07T17:06:41+00:00 weekly 0.7 https://trial.medpath.com/news/health-ministry-approves-introduction-of-new-shorter-more-efficacious-treatment-regimen-for 2024-09-07T16:38:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/health-ministry-approves-introduction-of-new-shorter-more-efficacious-treatment-regimen-for 2024-09-07T16:38:36+00:00 weekly 0.7 https://trial.medpath.com/news/intelligent-bio-solutions-advances-in-fda-approval-process-tipranks-com 2024-09-07T16:35:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intelligent-bio-solutions-advances-in-fda-approval-process-tipranks-com 2024-09-07T16:35:22+00:00 weekly 0.7 https://trial.medpath.com/news/baseline-characteristics-and-maintenance-therapy-choice-on-symptom-control-reliever 2024-09-07T16:27:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/baseline-characteristics-and-maintenance-therapy-choice-on-symptom-control-reliever 2024-09-07T16:27:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-official-clarifies-cgmp-expectations-for-investigational-drugs-raps 2024-09-07T16:00:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-official-clarifies-cgmp-expectations-for-investigational-drugs-raps 2024-09-07T16:00:21+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-new-csu-treatment-could-be-game-changing-tool-the-denver-post 2024-09-07T15:48:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-new-csu-treatment-could-be-game-changing-tool-the-denver-post 2024-09-07T15:48:23+00:00 weekly 0.7 https://trial.medpath.com/news/ifinatamab-deruxtecan-continues-to-demonstrate-promising-objective-response-rates-in 2024-09-07T15:35:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ifinatamab-deruxtecan-continues-to-demonstrate-promising-objective-response-rates-in 2024-09-07T15:35:45+00:00 weekly 0.7 https://trial.medpath.com/news/cbd-could-effectively-treat-leigh-syndrome-prolong-life-legal-reader 2024-09-07T15:13:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cbd-could-effectively-treat-leigh-syndrome-prolong-life-legal-reader 2024-09-07T15:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/the-oncfive-top-oncology-articles-for-the-week-of-9-1-onclive 2024-09-07T13:58:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-oncfive-top-oncology-articles-for-the-week-of-9-1-onclive 2024-09-07T13:58:51+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-experience-with-duchenne-muscular-dystrophy-gene-therapy-cgtlive-r 2024-09-07T13:09:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-experience-with-duchenne-muscular-dystrophy-gene-therapy-cgtlive-r 2024-09-07T13:09:25+00:00 weekly 0.7 https://trial.medpath.com/news/us-ipo-week-ahead-a-pair-of-biotechs-plan-to-complete-200-million-deals 2024-09-07T11:49:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-ipo-week-ahead-a-pair-of-biotechs-plan-to-complete-200-million-deals 2024-09-07T11:49:18+00:00 weekly 0.7 https://trial.medpath.com/news/ers-congress-2024-addresses-critical-ethical-challenges-of-ai-in-clinical-decision-making 2024-09-07T11:44:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ers-congress-2024-addresses-critical-ethical-challenges-of-ai-in-clinical-decision-making 2024-09-07T11:44:35+00:00 weekly 0.7 https://trial.medpath.com/news/bowel-cancer-trial-sees-all-patients-disease-free-in-huge-breakthrough-ladbible 2024-09-07T11:15:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bowel-cancer-trial-sees-all-patients-disease-free-in-huge-breakthrough-ladbible 2024-09-07T11:15:36+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-sanbexin-for-acute-ischemic-stroke 2024-09-07T10:58:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-sanbexin-for-acute-ischemic-stroke 2024-09-07T10:58:46+00:00 weekly 0.7 https://trial.medpath.com/news/the-evolution-and-clinical-applications-of-mrd-testing-in-lymphoma-pharmacy-times 2024-09-07T10:58:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-evolution-and-clinical-applications-of-mrd-testing-in-lymphoma-pharmacy-times 2024-09-07T10:58:46+00:00 weekly 0.7 https://trial.medpath.com/news/what-happened-in-optometry-this-week-september-2-september-6 2024-09-07T10:49:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-happened-in-optometry-this-week-september-2-september-6 2024-09-07T10:49:20+00:00 weekly 0.7 https://trial.medpath.com/news/how-rheumatoid-arthritis-and-down-syndrome-are-helping-researchers-find-treatments-for-alzheimer-s 2024-09-07T10:48:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-rheumatoid-arthritis-and-down-syndrome-are-helping-researchers-find-treatments-for-alzheimer-s 2024-09-07T10:48:08+00:00 weekly 0.7 https://trial.medpath.com/news/spidol-study-protocol-for-the-assessment-of-intrathecal-ziconotide-antalgic-efficacy-for-trials 2024-09-07T10:35:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spidol-study-protocol-for-the-assessment-of-intrathecal-ziconotide-antalgic-efficacy-for-trials 2024-09-07T10:35:20+00:00 weekly 0.7 https://trial.medpath.com/news/csf-proteomics-hints-at-how-apoe4-promotes-ad-and-how-a-drug-hinders-it-alzforum 2024-09-07T10:29:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/csf-proteomics-hints-at-how-apoe4-promotes-ad-and-how-a-drug-hinders-it-alzforum 2024-09-07T10:29:59+00:00 weekly 0.7 https://trial.medpath.com/news/ai-deep-learning-models-show-promise-in-accelerating-lung-cancer-biomarker-detection 2024-09-07T10:01:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-deep-learning-models-show-promise-in-accelerating-lung-cancer-biomarker-detection 2024-09-07T10:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/an-excellent-outcome-tavr-safe-and-effective-for-patients-in-their-nineties 2024-09-07T09:42:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-excellent-outcome-tavr-safe-and-effective-for-patients-in-their-nineties 2024-09-07T09:42:16+00:00 weekly 0.7 https://trial.medpath.com/news/novel-gene-therapies-and-transplant-options-reshape-sickle-cell-disease-treatment-landscape 2024-09-07T09:42:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-gene-therapies-and-transplant-options-reshape-sickle-cell-disease-treatment-landscape 2024-09-07T09:42:00+00:00 weekly 0.7 https://trial.medpath.com/news/2024-nccn-prostate-cancer-guidelines-updates-in-m1-cspc-treatment-urotoday 2024-09-07T09:32:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-nccn-prostate-cancer-guidelines-updates-in-m1-cspc-treatment-urotoday 2024-09-07T09:32:43+00:00 weekly 0.7 https://trial.medpath.com/news/billionaires-are-buying-viking-therapeutics-stock-left-and-right-should-you-follow-their-lead 2024-09-07T09:29:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/billionaires-are-buying-viking-therapeutics-stock-left-and-right-should-you-follow-their-lead 2024-09-07T09:29:33+00:00 weekly 0.7 https://trial.medpath.com/news/study-compares-safety-of-jak-inhibitors-between-adolescent-adult-patients-hcplive 2024-09-07T09:23:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-compares-safety-of-jak-inhibitors-between-adolescent-adult-patients-hcplive 2024-09-07T09:23:34+00:00 weekly 0.7 https://trial.medpath.com/news/weekly-review-neffy-pre-ordering-launches-trofinetide-data-and-more 2024-09-07T08:44:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weekly-review-neffy-pre-ordering-launches-trofinetide-data-and-more 2024-09-07T08:44:05+00:00 weekly 0.7 https://trial.medpath.com/news/research-suggests-psychedelics-are-well-tolerated-but-calls-for-improved-monitoring 2024-09-07T08:28:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-suggests-psychedelics-are-well-tolerated-but-calls-for-improved-monitoring 2024-09-07T08:28:01+00:00 weekly 0.7 https://trial.medpath.com/news/bioxcel-therapeutics-earns-buy-rating-on-promising-clinical-trials-and-market-potential 2024-09-07T08:27:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioxcel-therapeutics-earns-buy-rating-on-promising-clinical-trials-and-market-potential 2024-09-07T08:27:14+00:00 weekly 0.7 https://trial.medpath.com/news/sec-form-424b4-filed-by-qualigen-therapeutics-inc-quantisnow 2024-09-07T08:03:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sec-form-424b4-filed-by-qualigen-therapeutics-inc-quantisnow 2024-09-07T08:03:34+00:00 weekly 0.7 https://trial.medpath.com/news/reagan-udall-foundation-for-fda-facilitates-discussion-on-urgent-needs-in-ptsd-therapy 2024-09-07T08:01:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reagan-udall-foundation-for-fda-facilitates-discussion-on-urgent-needs-in-ptsd-therapy 2024-09-07T08:01:48+00:00 weekly 0.7 https://trial.medpath.com/news/managing-toxicities-in-cll-treatment-expert-insights-on-bcl2-and-btk-inhibitor-selection 2024-09-07T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/managing-toxicities-in-cll-treatment-expert-insights-on-bcl2-and-btk-inhibitor-selection 2024-09-07T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/depression-anxiety-improve-in-patients-enrolled-in-care-personalized-to-their-symptoms 2024-09-07T07:56:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/depression-anxiety-improve-in-patients-enrolled-in-care-personalized-to-their-symptoms 2024-09-07T07:56:17+00:00 weekly 0.7 https://trial.medpath.com/news/neurologylive-r-friday-5-september-6-2024 2024-09-07T07:10:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurologylive-r-friday-5-september-6-2024 2024-09-07T07:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-september-6-2024 2024-09-07T07:06:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgtlive-r-s-weekly-rewind-september-6-2024 2024-09-07T07:06:38+00:00 weekly 0.7 https://trial.medpath.com/news/mrna-car-t-descartes-08-s-potential-for-treating-myasthenia-gravis-cgtlive-r 2024-09-07T06:33:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mrna-car-t-descartes-08-s-potential-for-treating-myasthenia-gravis-cgtlive-r 2024-09-07T06:33:51+00:00 weekly 0.7 https://trial.medpath.com/news/longer-duration-of-adjuvant-trastuzumab-may-further-improve-dfs-rates-in-erbb2 2024-09-07T06:03:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longer-duration-of-adjuvant-trastuzumab-may-further-improve-dfs-rates-in-erbb2 2024-09-07T06:03:11+00:00 weekly 0.7 https://trial.medpath.com/news/gene-silencer-drug-shows-promise-in-treating-heart-condition-laboratory-equipment 2024-09-07T05:37:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-silencer-drug-shows-promise-in-treating-heart-condition-laboratory-equipment 2024-09-07T05:37:50+00:00 weekly 0.7 https://trial.medpath.com/news/d-vrd-improves-mrd-negativity-rates-in-newly-diagnosed-transplant-eligible-myeloma 2024-09-07T05:14:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/d-vrd-improves-mrd-negativity-rates-in-newly-diagnosed-transplant-eligible-myeloma 2024-09-07T05:14:09+00:00 weekly 0.7 https://trial.medpath.com/news/dr-ornstein-on-the-use-of-io-tki-doublets-in-non-ccrcc-onclive 2024-09-07T05:14:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-ornstein-on-the-use-of-io-tki-doublets-in-non-ccrcc-onclive 2024-09-07T05:14:07+00:00 weekly 0.7 https://trial.medpath.com/news/access-to-care-issues-complicate-prescribing-obesity-medications-clinical-advisor 2024-09-07T04:34:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/access-to-care-issues-complicate-prescribing-obesity-medications-clinical-advisor 2024-09-07T04:34:46+00:00 weekly 0.7 https://trial.medpath.com/news/vor-biopharma-s-promising-clinical-trials-and-strategic-developments-merit-a-buy-rating 2024-09-07T04:24:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vor-biopharma-s-promising-clinical-trials-and-strategic-developments-merit-a-buy-rating 2024-09-07T04:24:57+00:00 weekly 0.7 https://trial.medpath.com/news/nccn-adds-denileukin-diftitox-to-ctcl-clinical-practice-guidelines-in-oncology-onclive 2024-09-07T04:08:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nccn-adds-denileukin-diftitox-to-ctcl-clinical-practice-guidelines-in-oncology-onclive 2024-09-07T04:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/new-fda-approved-device-offers-hope-for-chronic-pain-sufferers 2024-09-07T04:00:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-fda-approved-device-offers-hope-for-chronic-pain-sufferers 2024-09-07T04:00:04+00:00 weekly 0.7 https://trial.medpath.com/news/text-messaging-shows-promise-for-lung-cancer-screening-eligibility-assessment-but-equity-gaps-persist 2024-09-07T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/text-messaging-shows-promise-for-lung-cancer-screening-eligibility-assessment-but-equity-gaps-persist 2024-09-07T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-higher-healthcare-barriers-for-chronic-liver-disease-patients-compared-to-other-chronic-conditions 2024-09-07T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-higher-healthcare-barriers-for-chronic-liver-disease-patients-compared-to-other-chronic-conditions 2024-09-07T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/obesity-drug-startup-raises-67m-vor-s-shielded-transplant-shows-promise 2024-09-07T03:54:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/obesity-drug-startup-raises-67m-vor-s-shielded-transplant-shows-promise 2024-09-07T03:54:39+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-safety-and-efficacy-evaluation-of-travoprost-intracameral-implant-based-on 2024-09-07T03:10:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-safety-and-efficacy-evaluation-of-travoprost-intracameral-implant-based-on 2024-09-07T03:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/advisory-committee-meeting-for-oral-sulopenem-occurring-september-9-2024 2024-09-07T03:04:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advisory-committee-meeting-for-oral-sulopenem-occurring-september-9-2024 2024-09-07T03:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/data-support-increased-subcutaneous-rituximab-use-in-non-hodgkin-lymphoma 2024-09-07T03:00:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-support-increased-subcutaneous-rituximab-use-in-non-hodgkin-lymphoma 2024-09-07T03:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/advanced-treatment-strategies-show-promise-in-improving-ptcl-patient-outcomes 2024-09-07T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advanced-treatment-strategies-show-promise-in-improving-ptcl-patient-outcomes 2024-09-07T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/donor-human-milk-for-preventing-necrotising-enterocolitis-in-very-preterm-or-very-low-pubmed 2024-09-07T02:43:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/donor-human-milk-for-preventing-necrotising-enterocolitis-in-very-preterm-or-very-low-pubmed 2024-09-07T02:43:46+00:00 weekly 0.7 https://trial.medpath.com/news/managing-drug-drug-interactions-so-many-drugs-so-little-evidence-jama-network 2024-09-07T01:43:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/managing-drug-drug-interactions-so-many-drugs-so-little-evidence-jama-network 2024-09-07T01:43:53+00:00 weekly 0.7 https://trial.medpath.com/news/acurastem-receives-cirm-grant-for-targeted-therapeutic-program-for-als-ftd-aftd 2024-09-07T01:14:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acurastem-receives-cirm-grant-for-targeted-therapeutic-program-for-als-ftd-aftd 2024-09-07T01:14:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-neoadjuvant-adjuvant-imfinzi-for-resectable-nsclc-the-cancer-letter 2024-09-07T00:18:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-neoadjuvant-adjuvant-imfinzi-for-resectable-nsclc-the-cancer-letter 2024-09-07T00:18:36+00:00 weekly 0.7 https://trial.medpath.com/news/i-can-t-imagine-doing-anything-else-as-a-nurse-meet-robin-dobbins-pediatric-oncology 2024-09-06T22:51:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/i-can-t-imagine-doing-anything-else-as-a-nurse-meet-robin-dobbins-pediatric-oncology 2024-09-06T22:51:53+00:00 weekly 0.7 https://trial.medpath.com/news/are-you-a-healthy-adult-above-18-years-of-age-you-may-be-qualified-to-take-part-in-a-uab 2024-09-06T21:59:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/are-you-a-healthy-adult-above-18-years-of-age-you-may-be-qualified-to-take-part-in-a-uab 2024-09-06T21:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/lundbeck-tests-its-most-promising-potential-migraine-candidate-in-ph1-combination-trial 2024-09-06T21:57:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lundbeck-tests-its-most-promising-potential-migraine-candidate-in-ph1-combination-trial 2024-09-06T21:57:09+00:00 weekly 0.7 https://trial.medpath.com/news/legendary-breast-cancer-researcher-carol-fabian-reflects-on-the-progress-of-research-and 2024-09-06T21:38:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/legendary-breast-cancer-researcher-carol-fabian-reflects-on-the-progress-of-research-and 2024-09-06T21:38:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-reviewers-voice-concerns-over-novel-uti-treatment-medpage-today 2024-09-06T21:33:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-reviewers-voice-concerns-over-novel-uti-treatment-medpage-today 2024-09-06T21:33:10+00:00 weekly 0.7 https://trial.medpath.com/news/autolus-start-thinking-about-obe-cel-pdufa-and-the-baby-bull-case-seeking-alpha 2024-09-06T21:12:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autolus-start-thinking-about-obe-cel-pdufa-and-the-baby-bull-case-seeking-alpha 2024-09-06T21:12:19+00:00 weekly 0.7 https://trial.medpath.com/news/elutia-celebrates-first-year-morningstar 2024-09-06T20:47:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elutia-celebrates-first-year-morningstar 2024-09-06T20:47:26+00:00 weekly 0.7 https://trial.medpath.com/news/relay-therapeutics-announces-webcast-to-report-rly-2608-data-on-september-9-2024 2024-09-06T20:08:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relay-therapeutics-announces-webcast-to-report-rly-2608-data-on-september-9-2024 2024-09-06T20:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-announces-positive-results-from-phase-iii-trial-of-nucala-mepolizumab-in-copd 2024-09-06T19:44:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-announces-positive-results-from-phase-iii-trial-of-nucala-mepolizumab-in-copd 2024-09-06T19:44:54+00:00 weekly 0.7 https://trial.medpath.com/news/fda-roundup-novavax-covid-19-vaccine-first-digital-therapeutic-for-gad-drug-topics 2024-09-06T19:38:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-roundup-novavax-covid-19-vaccine-first-digital-therapeutic-for-gad-drug-topics 2024-09-06T19:38:33+00:00 weekly 0.7 https://trial.medpath.com/news/exploring-afamelanotide-for-vitiligo-insights-into-the-cuv-105-phase-3-clinical-trial 2024-09-06T19:11:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exploring-afamelanotide-for-vitiligo-insights-into-the-cuv-105-phase-3-clinical-trial 2024-09-06T19:11:07+00:00 weekly 0.7 https://trial.medpath.com/news/first-on-podium-data-from-21-vascular-and-venous-clinical-trials-to-be-presented-pr-newswire 2024-09-06T19:00:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-on-podium-data-from-21-vascular-and-venous-clinical-trials-to-be-presented-pr-newswire 2024-09-06T19:00:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-nymalize-in-prefilled-enfit-syringes-drug-topics 2024-09-06T18:33:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-nymalize-in-prefilled-enfit-syringes-drug-topics 2024-09-06T18:33:13+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-ingelheim-to-advance-potential-new-treatment-for-geographic-atrophy-following 2024-09-06T18:23:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-ingelheim-to-advance-potential-new-treatment-for-geographic-atrophy-following 2024-09-06T18:23:53+00:00 weekly 0.7 https://trial.medpath.com/news/splash-clinical-announces-partnership-with-cambridge-cognition-globenewswire 2024-09-06T18:03:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/splash-clinical-announces-partnership-with-cambridge-cognition-globenewswire 2024-09-06T18:03:15+00:00 weekly 0.7 https://trial.medpath.com/news/development-of-a-core-outcome-set-for-studies-assessing-interventions-for-diabetes 2024-09-06T17:32:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/development-of-a-core-outcome-set-for-studies-assessing-interventions-for-diabetes 2024-09-06T17:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/cartesian-therapeutics-doses-first-patient-with-mrna-car-t-descartes-15-in-trial-for-r-r 2024-09-06T17:19:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cartesian-therapeutics-doses-first-patient-with-mrna-car-t-descartes-15-in-trial-for-r-r 2024-09-06T17:19:15+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-shares-keep-buy-rating-on-successful-phase-iii-trial-results-investing-com 2024-09-06T17:03:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-shares-keep-buy-rating-on-successful-phase-iii-trial-results-investing-com 2024-09-06T17:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/dr-patel-on-the-fda-approval-of-durvalumab-plus-chemotherapy-for-nsclc-onclive 2024-09-06T17:02:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-patel-on-the-fda-approval-of-durvalumab-plus-chemotherapy-for-nsclc-onclive 2024-09-06T17:02:39+00:00 weekly 0.7 https://trial.medpath.com/news/milestone-partner-ji-xing-pharmaceuticals-ltd-announces-positive-topline-results-from-the 2024-09-06T16:56:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/milestone-partner-ji-xing-pharmaceuticals-ltd-announces-positive-topline-results-from-the 2024-09-06T16:56:15+00:00 weekly 0.7 https://trial.medpath.com/news/alopexx-announces-investment-from-biotech-consortia-inc-biospace 2024-09-06T16:56:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alopexx-announces-investment-from-biotech-consortia-inc-biospace 2024-09-06T16:56:15+00:00 weekly 0.7 https://trial.medpath.com/news/ventyx-biosciences-announces-initiation-of-dosing-in-a-phase-2a-trial-of-vtx3232-in-biospace 2024-09-06T16:56:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ventyx-biosciences-announces-initiation-of-dosing-in-a-phase-2a-trial-of-vtx3232-in-biospace 2024-09-06T16:56:12+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-keynote-789-trial-evaluates-pembrolizumab-plus-chemotherapy-in-egfr 2024-09-06T16:52:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-keynote-789-trial-evaluates-pembrolizumab-plus-chemotherapy-in-egfr 2024-09-06T16:52:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-confirms-acceptability-of-palatin-s-remaining-phase-3-pivotal-clinical-trials-for-pl9643-in-ded 2024-09-06T16:46:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-confirms-acceptability-of-palatin-s-remaining-phase-3-pivotal-clinical-trials-for-pl9643-in-ded 2024-09-06T16:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/amid-shortages-us-allows-expanded-production-of-adhd-drug-vyvanse-clinical-advisor 2024-09-06T16:34:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amid-shortages-us-allows-expanded-production-of-adhd-drug-vyvanse-clinical-advisor 2024-09-06T16:34:59+00:00 weekly 0.7 https://trial.medpath.com/news/new-clinical-studies-and-classification-criteria-advance-understanding-of-axial-psa-treatment 2024-09-06T16:00:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-clinical-studies-and-classification-criteria-advance-understanding-of-axial-psa-treatment 2024-09-06T16:00:24+00:00 weekly 0.7 https://trial.medpath.com/news/ai-drug-discovery-trial-reveals-promise-and-challenges-of-using-the-tech-pymnts-com 2024-09-06T15:48:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-drug-discovery-trial-reveals-promise-and-challenges-of-using-the-tech-pymnts-com 2024-09-06T15:48:22+00:00 weekly 0.7 https://trial.medpath.com/news/eu-court-halts-commission-s-ban-on-drug-for-rare-liver-disease-yahoo-news-uk 2024-09-06T15:44:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-court-halts-commission-s-ban-on-drug-for-rare-liver-disease-yahoo-news-uk 2024-09-06T15:44:28+00:00 weekly 0.7 https://trial.medpath.com/news/strides-gains-usfda-approval-for-theophylline-extended-release-tablets-300-mg-and-450-mg 2024-09-06T15:17:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/strides-gains-usfda-approval-for-theophylline-extended-release-tablets-300-mg-and-450-mg 2024-09-06T15:17:10+00:00 weekly 0.7 https://trial.medpath.com/news/drug-drug-interactions-and-the-clinical-tolerability-of-colchicine-among-patients-with-covid-19 2024-09-06T15:15:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-drug-interactions-and-the-clinical-tolerability-of-colchicine-among-patients-with-covid-19 2024-09-06T15:15:57+00:00 weekly 0.7 https://trial.medpath.com/news/milk-elimination-diet-shows-promise-as-first-line-therapy-for-children-with-eoe 2024-09-06T15:13:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/milk-elimination-diet-shows-promise-as-first-line-therapy-for-children-with-eoe 2024-09-06T15:13:48+00:00 weekly 0.7 https://trial.medpath.com/news/florida-cancer-specialists-presents-real-world-evidence-research-on-multiple-myeloma-at-international-meeting 2024-09-06T14:59:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/florida-cancer-specialists-presents-real-world-evidence-research-on-multiple-myeloma-at-international-meeting 2024-09-06T14:59:00+00:00 weekly 0.7 https://trial.medpath.com/news/prescription-digital-therapeutic-reduces-monthly-migraine-days-phase-3-study-shows 2024-09-06T14:51:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prescription-digital-therapeutic-reduces-monthly-migraine-days-phase-3-study-shows 2024-09-06T14:51:13+00:00 weekly 0.7 https://trial.medpath.com/news/findings-from-cobalt-trial-including-external-control-arm-globenewswire 2024-09-06T14:32:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/findings-from-cobalt-trial-including-external-control-arm-globenewswire 2024-09-06T14:32:52+00:00 weekly 0.7 https://trial.medpath.com/news/gastrointestinal-chemotherapy-tweak-can-reduce-side-effects-inside-precision-medicine 2024-09-06T14:29:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gastrointestinal-chemotherapy-tweak-can-reduce-side-effects-inside-precision-medicine 2024-09-06T14:29:32+00:00 weekly 0.7 https://trial.medpath.com/news/future-of-crispr-gene-editing-technologies-herald-landmark-clinical-trials 2024-09-06T14:23:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/future-of-crispr-gene-editing-technologies-herald-landmark-clinical-trials 2024-09-06T14:23:37+00:00 weekly 0.7 https://trial.medpath.com/news/deuterium-depletion-is-the-key-to-getting-a-breakthrough-in-cancer-therapy 2024-09-06T14:17:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/deuterium-depletion-is-the-key-to-getting-a-breakthrough-in-cancer-therapy 2024-09-06T14:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/twice-yearly-azithromycin-distribution-reduces-childhood-mortality-in-rural-niger 2024-09-06T14:05:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/twice-yearly-azithromycin-distribution-reduces-childhood-mortality-in-rural-niger 2024-09-06T14:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/duke-professor-s-research-leads-to-first-drug-for-type-of-liver-disease-the-chronicle 2024-09-06T13:26:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/duke-professor-s-research-leads-to-first-drug-for-type-of-liver-disease-the-chronicle 2024-09-06T13:26:16+00:00 weekly 0.7 https://trial.medpath.com/news/lenvatinib-and-pembrolizumab-combo-breaks-new-ground-in-non-clear-cell-rcc 2024-09-06T13:04:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenvatinib-and-pembrolizumab-combo-breaks-new-ground-in-non-clear-cell-rcc 2024-09-06T13:04:44+00:00 weekly 0.7 https://trial.medpath.com/news/cytonics-announces-completion-of-enrollment-for-phase-1-clinical-study-evaluating-cyt 2024-09-06T12:57:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytonics-announces-completion-of-enrollment-for-phase-1-clinical-study-evaluating-cyt 2024-09-06T12:57:56+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-to-present-data-from-13-clinical-studies-at-esmo-2024-featuring-its-pr-newswire 2024-09-06T12:54:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akeso-to-present-data-from-13-clinical-studies-at-esmo-2024-featuring-its-pr-newswire 2024-09-06T12:54:46+00:00 weekly 0.7 https://trial.medpath.com/news/novel-cell-free-dna-assays-expand-the-reach-of-mrd-detection-in-lymphoma-onclive 2024-09-06T12:42:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-cell-free-dna-assays-expand-the-reach-of-mrd-detection-in-lymphoma-onclive 2024-09-06T12:42:33+00:00 weekly 0.7 https://trial.medpath.com/news/craig-hallum-initiated-coverage-on-cardiff-oncology-with-a-new-price-target-quantisnow 2024-09-06T12:16:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/craig-hallum-initiated-coverage-on-cardiff-oncology-with-a-new-price-target-quantisnow 2024-09-06T12:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/shingles-episodes-linked-to-20-higher-risk-of-cognitive-decline-brigham-study-reveals 2024-09-06T12:08:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shingles-episodes-linked-to-20-higher-risk-of-cognitive-decline-brigham-study-reveals 2024-09-06T12:08:37+00:00 weekly 0.7 https://trial.medpath.com/news/puretech-founded-entity-vor-bio-announces-new-clinical-data-validating-approach-of 2024-09-06T12:00:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/puretech-founded-entity-vor-bio-announces-new-clinical-data-validating-approach-of 2024-09-06T12:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/psyence-biomed-announces-the-signing-of-a-conditional-binding-term-sheet-for-the-morningstar 2024-09-06T11:57:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psyence-biomed-announces-the-signing-of-a-conditional-binding-term-sheet-for-the-morningstar 2024-09-06T11:57:40+00:00 weekly 0.7 https://trial.medpath.com/news/aurinia-doses-first-subject-in-phase-ia-trial-of-aur200-for-autoimmune-diseases 2024-09-06T11:52:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aurinia-doses-first-subject-in-phase-ia-trial-of-aur200-for-autoimmune-diseases 2024-09-06T11:52:46+00:00 weekly 0.7 https://trial.medpath.com/news/the-marcus-foundation-makes-major-25-9-million-award-to-advance-lifesaving-stroke 2024-09-06T11:13:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-marcus-foundation-makes-major-25-9-million-award-to-advance-lifesaving-stroke 2024-09-06T11:13:17+00:00 weekly 0.7 https://trial.medpath.com/news/cell-therapy-weekly-fda-grants-odd-for-retinal-gene-therapy-regmednet 2024-09-06T11:06:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cell-therapy-weekly-fda-grants-odd-for-retinal-gene-therapy-regmednet 2024-09-06T11:06:21+00:00 weekly 0.7 https://trial.medpath.com/news/cd47-inhibitor-drug-clinical-trials-market-outlook-to-2028-globenewswire 2024-09-06T10:51:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cd47-inhibitor-drug-clinical-trials-market-outlook-to-2028-globenewswire 2024-09-06T10:51:39+00:00 weekly 0.7 https://trial.medpath.com/news/kalvista-pharmaceuticals-presents-sebetralstat-data-at-bradykinin-symposium-2024 2024-09-06T10:33:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kalvista-pharmaceuticals-presents-sebetralstat-data-at-bradykinin-symposium-2024 2024-09-06T10:33:57+00:00 weekly 0.7 https://trial.medpath.com/news/living-with-multiple-myeloma-doctor-becomes-powerful-resource-and-patient-advocate 2024-09-06T10:23:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/living-with-multiple-myeloma-doctor-becomes-powerful-resource-and-patient-advocate 2024-09-06T10:23:34+00:00 weekly 0.7 https://trial.medpath.com/news/next-generation-precision-medicine-for-suicidality-prevention-translational-psychiatry 2024-09-06T09:38:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/next-generation-precision-medicine-for-suicidality-prevention-translational-psychiatry 2024-09-06T09:38:38+00:00 weekly 0.7 https://trial.medpath.com/news/neutrophil-exhaustion-and-impaired-functionality-in-psoriatic-arthritis-patients-frontiers 2024-09-06T09:10:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neutrophil-exhaustion-and-impaired-functionality-in-psoriatic-arthritis-patients-frontiers 2024-09-06T09:10:19+00:00 weekly 0.7 https://trial.medpath.com/news/strides-pharma-hits-all-time-high-after-usfda-approval-for-this-drug-news-on-markets 2024-09-06T08:31:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/strides-pharma-hits-all-time-high-after-usfda-approval-for-this-drug-news-on-markets 2024-09-06T08:31:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-drug-approval-decisions-expected-in-october-2024-mpr-empr-com 2024-09-06T08:27:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-drug-approval-decisions-expected-in-october-2024-mpr-empr-com 2024-09-06T08:27:35+00:00 weekly 0.7 https://trial.medpath.com/news/in8bio-cuts-staff-and-pipeline-to-focus-on-aml-cell-therapy-clinical-trials-arena 2024-09-06T08:23:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in8bio-cuts-staff-and-pipeline-to-focus-on-aml-cell-therapy-clinical-trials-arena 2024-09-06T08:23:21+00:00 weekly 0.7 https://trial.medpath.com/news/sun-pharma-and-israel-based-moebius-medical-announce-usfda-grant-of-fast-track 2024-09-06T08:20:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sun-pharma-and-israel-based-moebius-medical-announce-usfda-grant-of-fast-track 2024-09-06T08:20:52+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-asthma-drug-shows-promise-in-treating-chronic-lung-disease-bnn-bloomberg 2024-09-06T08:10:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-asthma-drug-shows-promise-in-treating-chronic-lung-disease-bnn-bloomberg 2024-09-06T08:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/lykos-ceo-to-depart-after-fda-rejection-layoffs-biopharma-dive 2024-09-06T07:52:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lykos-ceo-to-depart-after-fda-rejection-layoffs-biopharma-dive 2024-09-06T07:52:54+00:00 weekly 0.7 https://trial.medpath.com/news/atopic-dermatitis-market-set-to-reach-16-7b-by-2030-driving-innovation-in-treatment-options 2024-09-06T07:37:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atopic-dermatitis-market-set-to-reach-16-7b-by-2030-driving-innovation-in-treatment-options 2024-09-06T07:37:31+00:00 weekly 0.7 https://trial.medpath.com/news/sept-5-2024-clinical-trials-hope-to-curb-and-reverse-alzheimer-s-evs-drive-a-shift-for-firefighters 2024-09-06T07:25:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sept-5-2024-clinical-trials-hope-to-curb-and-reverse-alzheimer-s-evs-drive-a-shift-for-firefighters 2024-09-06T07:25:40+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-enrolled-in-phase-1b-2-triplet-therapy-trial-of-rezlidhia-in-midh1-aml 2024-09-06T07:09:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-enrolled-in-phase-1b-2-triplet-therapy-trial-of-rezlidhia-in-midh1-aml 2024-09-06T07:09:41+00:00 weekly 0.7 https://trial.medpath.com/news/international-consensus-supports-asthma-biologic-use-during-pregnancy-with-shared-decision-making 2024-09-06T07:00:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/international-consensus-supports-asthma-biologic-use-during-pregnancy-with-shared-decision-making 2024-09-06T07:00:24+00:00 weekly 0.7 https://trial.medpath.com/news/verastem-s-path-to-fda-approval-high-risk-high-reward-oncology-opportunity 2024-09-06T06:25:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verastem-s-path-to-fda-approval-high-risk-high-reward-oncology-opportunity 2024-09-06T06:25:57+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-certepetide-in-cholangiocarcinoma-onclive 2024-09-06T06:24:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-certepetide-in-cholangiocarcinoma-onclive 2024-09-06T06:24:13+00:00 weekly 0.7 https://trial.medpath.com/news/a-small-step-towards-a-big-mission-world-s-first-ultradx-received-first-clinical-approval 2024-09-06T06:20:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-small-step-towards-a-big-mission-world-s-first-ultradx-received-first-clinical-approval 2024-09-06T06:20:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-new-drug-approvals-in-august-include-a-dupixent-competitor-a-targeted-glioma 2024-09-06T06:15:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-s-new-drug-approvals-in-august-include-a-dupixent-competitor-a-targeted-glioma 2024-09-06T06:15:37+00:00 weekly 0.7 https://trial.medpath.com/news/pyrotinib-plus-metronomic-vinorelbine-is-active-in-her2-advanced-breast-cancer-after 2024-09-06T06:06:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pyrotinib-plus-metronomic-vinorelbine-is-active-in-her2-advanced-breast-cancer-after 2024-09-06T06:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/global-bispecific-antibody-drug-conjugates-bispecific-adc-clinical-trials-commercial 2024-09-06T05:53:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-bispecific-antibody-drug-conjugates-bispecific-adc-clinical-trials-commercial 2024-09-06T05:53:37+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-broad-spectrum-malaria-therapy-hunt-mirage-news 2024-09-06T05:25:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-broad-spectrum-malaria-therapy-hunt-mirage-news 2024-09-06T05:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/vanda-s-struggles-persist-despite-new-drug-launches-and-takeover-bids-seeking-alpha 2024-09-06T05:24:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vanda-s-struggles-persist-despite-new-drug-launches-and-takeover-bids-seeking-alpha 2024-09-06T05:24:46+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-hope-a-revolutionary-advance-in-treating-brain-cancer-called-glioma-survivornet 2024-09-06T05:06:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-hope-a-revolutionary-advance-in-treating-brain-cancer-called-glioma-survivornet 2024-09-06T05:06:09+00:00 weekly 0.7 https://trial.medpath.com/news/ocuphire-pharma-doses-first-patient-in-phase-3-vega-3-clinical-trial-ophthalmology-times 2024-09-06T04:40:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocuphire-pharma-doses-first-patient-in-phase-3-vega-3-clinical-trial-ophthalmology-times 2024-09-06T04:40:36+00:00 weekly 0.7 https://trial.medpath.com/news/atsena-therapeutics-announces-12-month-safety-and-efficacy-data-from-phase-i-ii-clinical 2024-09-06T04:32:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atsena-therapeutics-announces-12-month-safety-and-efficacy-data-from-phase-i-ii-clinical 2024-09-06T04:32:00+00:00 weekly 0.7 https://trial.medpath.com/news/hilleman-and-bharat-biotech-launch-oral-cholera-vaccine-in-india-bioprocess-international 2024-09-06T04:06:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hilleman-and-bharat-biotech-launch-oral-cholera-vaccine-in-india-bioprocess-international 2024-09-06T04:06:50+00:00 weekly 0.7 https://trial.medpath.com/news/think-surgical-receives-fda-510-k-clearance-for-zimmer-biomet-persona-knee-on-tmini 2024-09-06T04:05:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/think-surgical-receives-fda-510-k-clearance-for-zimmer-biomet-persona-knee-on-tmini 2024-09-06T04:05:57+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-mpox-mrna-vaccine-shows-early-promise-in-monkey-study-clinical-trials-arena 2024-09-06T03:28:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-mpox-mrna-vaccine-shows-early-promise-in-monkey-study-clinical-trials-arena 2024-09-06T03:28:01+00:00 weekly 0.7 https://trial.medpath.com/news/largest-ever-phage-therapy-trial-shows-promise-for-uti-treatment-c-en 2024-09-06T03:16:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/largest-ever-phage-therapy-trial-shows-promise-for-uti-treatment-c-en 2024-09-06T03:16:59+00:00 weekly 0.7 https://trial.medpath.com/news/lupin-share-price-hits-52-week-high-on-launch-of-overactive-bladder-drug-in-us-mint 2024-09-06T02:54:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lupin-share-price-hits-52-week-high-on-launch-of-overactive-bladder-drug-in-us-mint 2024-09-06T02:54:31+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-study-explores-efficacy-of-light-activated-therapy-in-adolescents-undergoing 2024-09-06T02:53:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-study-explores-efficacy-of-light-activated-therapy-in-adolescents-undergoing 2024-09-06T02:53:53+00:00 weekly 0.7 https://trial.medpath.com/news/tisagenlecleucel-moves-to-earlier-lines-of-therapy-for-pediatric-young-adults-with 2024-09-06T02:23:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tisagenlecleucel-moves-to-earlier-lines-of-therapy-for-pediatric-young-adults-with 2024-09-06T02:23:24+00:00 weekly 0.7 https://trial.medpath.com/news/nimmune-and-biotherapeutics-form-strategic-alliance-to-accelerate-precision-medicine-development-for-autoimmune-diseases 2024-09-06T02:09:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nimmune-and-biotherapeutics-form-strategic-alliance-to-accelerate-precision-medicine-development-for-autoimmune-diseases 2024-09-06T02:09:20+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-nox-inhibitors-for-treating-fibrotic-diseases-and-cancer 2024-09-06T02:04:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancing-nox-inhibitors-for-treating-fibrotic-diseases-and-cancer 2024-09-06T02:04:56+00:00 weekly 0.7 https://trial.medpath.com/news/new-partners-for-phase-2-trial-of-next-gen-lithium-therapy-al001-alzheimer-s-news-today 2024-09-06T01:43:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-partners-for-phase-2-trial-of-next-gen-lithium-therapy-al001-alzheimer-s-news-today 2024-09-06T01:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/esc-congress-recap-high-impact-clinical-trials-with-deepak-bhatt-md-mph-mba 2024-09-06T01:36:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esc-congress-recap-high-impact-clinical-trials-with-deepak-bhatt-md-mph-mba 2024-09-06T01:36:34+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-aim-to-confirm-benefits-of-non-hormonal-therapy-for-certain-prostate-cancer-patients 2024-09-06T01:32:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-aim-to-confirm-benefits-of-non-hormonal-therapy-for-certain-prostate-cancer-patients 2024-09-06T01:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/egenesis-lands-191m-to-advance-xenotransplantation-into-clinical-trials 2024-09-06T01:31:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/egenesis-lands-191m-to-advance-xenotransplantation-into-clinical-trials 2024-09-06T01:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/travere-therapeutics-announces-full-fda-approval-of-filspari-r-sparsentan-the-only 2024-09-06T01:19:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/travere-therapeutics-announces-full-fda-approval-of-filspari-r-sparsentan-the-only 2024-09-06T01:19:50+00:00 weekly 0.7 https://trial.medpath.com/news/oppenheimer-upgrades-ascendis-pharma-shares-on-potential-drug-launches 2024-09-06T01:04:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oppenheimer-upgrades-ascendis-pharma-shares-on-potential-drug-launches 2024-09-06T01:04:27+00:00 weekly 0.7 https://trial.medpath.com/news/decentralized-clinical-trials-show-significant-growth-in-2024-driving-improved-patient-diversity-and-retention 2024-09-06T00:41:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/decentralized-clinical-trials-show-significant-growth-in-2024-driving-improved-patient-diversity-and-retention 2024-09-06T00:41:50+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-study-measures-lenire-s-effectiveness-in-treating-tinnitus 2024-09-06T00:21:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-study-measures-lenire-s-effectiveness-in-treating-tinnitus 2024-09-06T00:21:42+00:00 weekly 0.7 https://trial.medpath.com/news/amneal-gains-fda-approval-for-new-oncology-drug-boruzu-investing-com 2024-09-06T00:00:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amneal-gains-fda-approval-for-new-oncology-drug-boruzu-investing-com 2024-09-06T00:00:23+00:00 weekly 0.7 https://trial.medpath.com/news/hoth-stock-up-as-lead-drug-heals-skin-toxicities-in 2024-09-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hoth-stock-up-as-lead-drug-heals-skin-toxicities-in 2024-09-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cleo-commences-u-s-clinical-trials 2024-09-05T23:29:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cleo-commences-u-s-clinical-trials 2024-09-05T23:29:25+00:00 weekly 0.7 https://trial.medpath.com/news/tempo-therapeutics-announces-first-patient-dosed-in-clinical-trial-of-tt101-for-tissue 2024-09-05T23:27:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tempo-therapeutics-announces-first-patient-dosed-in-clinical-trial-of-tt101-for-tissue 2024-09-05T23:27:04+00:00 weekly 0.7 https://trial.medpath.com/news/vesper-bio-reports-data-from-phase-i-frontotemporal-dementia-treatment-trial 2024-09-05T22:57:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vesper-bio-reports-data-from-phase-i-frontotemporal-dementia-treatment-trial 2024-09-05T22:57:54+00:00 weekly 0.7 https://trial.medpath.com/news/usf-researcher-led-clinical-trial-for-new-parkinson-s-medication-tampa-bay-times 2024-09-05T22:54:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/usf-researcher-led-clinical-trial-for-new-parkinson-s-medication-tampa-bay-times 2024-09-05T22:54:43+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-restores-quality-of-life-for-concord-township-woman-news-herald 2024-09-05T22:53:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-restores-quality-of-life-for-concord-township-woman-news-herald 2024-09-05T22:53:10+00:00 weekly 0.7 https://trial.medpath.com/news/changes-in-skeletal-muscle-mass-in-the-first-3-months-following-gastrointestinal-cancer-surgery 2024-09-05T22:48:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/changes-in-skeletal-muscle-mass-in-the-first-3-months-following-gastrointestinal-cancer-surgery 2024-09-05T22:48:46+00:00 weekly 0.7 https://trial.medpath.com/news/efsitora-demonstrates-non-inferiority-vs-insulin-glargine-degludec-for-type-2-diabetes 2024-09-05T22:33:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efsitora-demonstrates-non-inferiority-vs-insulin-glargine-degludec-for-type-2-diabetes 2024-09-05T22:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/in-this-month-s-e-news-september-2024-health-care-compliance-association-hcca 2024-09-05T21:59:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-this-month-s-e-news-september-2024-health-care-compliance-association-hcca 2024-09-05T21:59:56+00:00 weekly 0.7 https://trial.medpath.com/news/stifel-initiates-coverage-on-oric-pharmaceuticals-with-buy-rating-and-20-target 2024-09-05T21:08:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stifel-initiates-coverage-on-oric-pharmaceuticals-with-buy-rating-and-20-target 2024-09-05T21:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-covid-19-vaccine-for-fall-and-winter-wsaz 2024-09-05T20:55:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-covid-19-vaccine-for-fall-and-winter-wsaz 2024-09-05T20:55:29+00:00 weekly 0.7 https://trial.medpath.com/news/ai-tools-help-avoid-patient-dropouts-nonadherence-in-clinical-trials-inside-health-policy 2024-09-05T20:51:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-tools-help-avoid-patient-dropouts-nonadherence-in-clinical-trials-inside-health-policy 2024-09-05T20:51:22+00:00 weekly 0.7 https://trial.medpath.com/news/incyte-wins-fda-approval-for-niktimvo-considers-future-delaware-business-times 2024-09-05T20:29:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/incyte-wins-fda-approval-for-niktimvo-considers-future-delaware-business-times 2024-09-05T20:29:21+00:00 weekly 0.7 https://trial.medpath.com/news/immuron-plans-phase-2-trial-for-imm-529-following-fda-review-biospace 2024-09-05T20:19:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immuron-plans-phase-2-trial-for-imm-529-following-fda-review-biospace 2024-09-05T20:19:04+00:00 weekly 0.7 https://trial.medpath.com/news/sacituzumab-govitecan-in-advanced-urothelial-cancer-after-ici-therapy-the-asco-post 2024-09-05T20:13:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sacituzumab-govitecan-in-advanced-urothelial-cancer-after-ici-therapy-the-asco-post 2024-09-05T20:13:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-foundationone-tests-for-olaparib-combo-in-brca-mutated-mcrpc 2024-09-05T20:08:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-foundationone-tests-for-olaparib-combo-in-brca-mutated-mcrpc 2024-09-05T20:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-awards-orphan-drug-designation-to-abd-147-for-neuroendocrine-carcinoma 2024-09-05T20:01:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-awards-orphan-drug-designation-to-abd-147-for-neuroendocrine-carcinoma 2024-09-05T20:01:15+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-new-covid-19-vaccines-here-s-what-to-know-and-where-to-get-them 2024-09-05T19:35:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approved-new-covid-19-vaccines-here-s-what-to-know-and-where-to-get-them 2024-09-05T19:35:53+00:00 weekly 0.7 https://trial.medpath.com/news/kalvista-pharmaceuticals-reports-first-fiscal-quarter-results-and-provides-operational-update 2024-09-05T19:07:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kalvista-pharmaceuticals-reports-first-fiscal-quarter-results-and-provides-operational-update 2024-09-05T19:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-s-nusinersen-shows-efficacy-compared-to-sham-treatment-at-experimental-higher-dose 2024-09-05T19:05:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biogen-s-nusinersen-shows-efficacy-compared-to-sham-treatment-at-experimental-higher-dose 2024-09-05T19:05:40+00:00 weekly 0.7 https://trial.medpath.com/news/palisade-bio-reports-data-demonstrating-pde4b-expression-in-patient-cohorts-could-be 2024-09-05T18:54:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/palisade-bio-reports-data-demonstrating-pde4b-expression-in-patient-cohorts-could-be 2024-09-05T18:54:12+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-research-focus-32nd-edition-cromos-pharma 2024-09-05T18:35:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-research-focus-32nd-edition-cromos-pharma 2024-09-05T18:35:50+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-receives-us-fda-fast-track-designation-for-ibi363-as-monotherapy-for-advanced-melanoma 2024-09-05T18:30:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovent-receives-us-fda-fast-track-designation-for-ibi363-as-monotherapy-for-advanced-melanoma 2024-09-05T18:30:56+00:00 weekly 0.7 https://trial.medpath.com/news/safe-pro-ai-completes-united-nations-development-programme-s-purchase-order-accesswire 2024-09-05T18:30:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safe-pro-ai-completes-united-nations-development-programme-s-purchase-order-accesswire 2024-09-05T18:30:26+00:00 weekly 0.7 https://trial.medpath.com/news/skyline-therapeutics-receives-orphan-drug-designation-from-fda-for-skg1108 2024-09-05T18:26:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/skyline-therapeutics-receives-orphan-drug-designation-from-fda-for-skg1108 2024-09-05T18:26:20+00:00 weekly 0.7 https://trial.medpath.com/news/um-cancer-treatment-reaches-human-clinical-trials-news-montanakaimin-com 2024-09-05T18:16:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/um-cancer-treatment-reaches-human-clinical-trials-news-montanakaimin-com 2024-09-05T18:16:03+00:00 weekly 0.7